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RÉSUMÉ 
 Caractérisation détaillée de l’interaction entre NS3 et NS5 dans le complexe de 
réplication du virus du Nil occidental pendant la synthèse d’ARN de polarité positive 
 
Par 
Carolin Brand 
Programme de biochimie 
 
Mémoire présenté à la Faculté de Médecine et des Sciences de la Santé en vue de 
l’obtention du diplôme de maitre ès sciences (M. Sc.) en biochimie, Faculté de médecine et 
des sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Les Flavivirus transmis par les moustiques comme le virus du Nil occidental, le virus de la 
dengue, le virus de la fièvre jaune, le virus de l’encéphalite japonaise et le virus Zika 
constituent des préoccupations croissantes de santé publique. Ils se sont répandus dans le 
monde au cours des dernières décennies, et les épidémies sont devenues plus fréquentes et 
plus sévères. Chaque année, des millions de personnes sont infectées et environ 50 000 
patients décèdent d’infections à Flavivirus. Malgré les nombreux efforts de recherche, il n’y 
a actuellement aucun médicament antiviral spécifique disponible, et des nouvelles 
stratégies antivirales sont indispensables. Comprendre comment les Flavivirus fonctionnent 
au niveau moléculaire aidera à découvrir des nouvelles cibles pour l'intervention 
thérapeutique. 
 
Les Flavivirus ont un génome d'ARN simple brin de polarité positive qui code pour trois 
protéines structurales et huit protéines non structurales. Seules deux des huit protéines non 
structurales ont des activités enzymatiques. NS3 possède un domaine protéase et un 
domaine hélicase, et NS5 a un domaine méthyl- et guanylyltransférase et un domaine ARN 
polymérase ARN-dépendante. Ensemble, ils répliquent le génome viral. Ici, nous 
caractérisons l'interaction entre NS3 et NS5 dans le complexe de réplication du virus du Nil 
occidental pendant la synthèse d’ARN de polarité positive. 
 
Un modèle d'interaction comprenant NS3, NS5 et l’ARN viral a été développé basé sur des 
structures cristallines connues ainsi que des activités enzymatiques des deux protéines 
individuelles, et ce modèle a été soumis à des simulations de dynamique moléculaire. Les 
interactions potentielles entre les protéines NS3 et NS5 ont été identifiées. Les résidus 
impliqués dans ces interactions ont été mutés dans un réplicon du virus du Nil occidental et 
les effets de ces mutations sur la réplication virale ont été évalués. Une région particulière à 
la surface de la protéine NS3 a été identifiée comme étant cruciale pour la réplication 
virale, très probablement parce qu'elle interagit avec NS5. Cette région pourrait être une 
cible attrayante pour la recherche de composés qui pourraient interférer avec l'interaction 
entre NS3 et NS5 et donc posséder un potentiel antiviral intéressant. 
 
Mots clés : Flavivirus, virus du Nil occidental, complexe de réplication, interaction entre 
NS3 et NS5 
SUMMARY 
 In-depth characterization of the NS3:NS5 interaction within the West Nile virus 
replicase complex during positive strand RNA synthesis 
 
By 
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Thesis presented at the Faculty of Medicine and Health Sciences for the fulfillment of the 
Master degree diploma Master of Science (M. Sc.) in biochemistry, Faculty of medicine 
and health sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Mosquito-borne Flaviviruses like West Nile virus, Dengue virus, Yellow Fever virus, 
Japanese encephalitis virus, and Zika virus are increasing public health concerns. They 
have spread globally during the past decades, and outbreaks have recently become more 
frequent and more severe. Every year, millions of people are infected, and approximately 
50,000 patients die from Flavivirus infections. Despite extensive research efforts, there are 
currently no specific antiviral drugs available, and new antiviral strategies are greatly 
needed. Understanding how Flaviviruses work on a molecular level will help in uncovering 
new points for therapeutic intervention. 
 
Flaviviruses have a single-stranded RNA genome of positive polarity that encodes three 
structural and eight non-structural proteins. Only two of the eight non-structural proteins 
have enzymatic activities. NS3 has an N-terminal protease domain and a C-terminal 
helicase domain, and NS5 has an N-terminal capping enzyme domain and a C-terminal 
RNA-dependent RNA polymerase domain. Together, they replicate the viral genome. Here 
we characterize the NS3:NS5 interaction within the West Nile virus RNA replicase 
complex during positive strand synthesis. 
 
An interaction model including NS3, NS5 and viral RNA was developed based on the 
known crystal structures as well as enzymatic activities of the two individual proteins, and 
this model was subjected to molecular dynamics simulations. Potential interactions between 
the NS3 and NS5 proteins were identified. Residues involved in these interactions were 
mutated in a West Nile virus replicon, and the effects of these mutations on viral replication 
were evaluated. One particular region on the surface of the NS3 protein was identified to be 
crucial for viral replication, most likely because it mediates the interaction with NS5. This 
region might be an attractive target for the search of compounds that could interfere with 
the NS3:NS5 interaction and therefore possess an interesting antiviral potential.    
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INTRODUCTION 
Flaviviruses 
The family Flaviviridae contains four genera, namely Flavivirus, Hepacivirus, Pegivirus 
and Pestivirus with 53, 1, 2 and 4 species, respectively (Figure 1) (International Committee 
on Taxonomy of Viruses, 2015). However, not all Flaviviridae viruses have been assigned 
to one of these genera, and they remain unclassified (Papageorgiou et al., 2016). Some 
viruses of the Flavivirus genus are specific to arthropods whereas others are transmissible 
to vertebrates, and the latter group can be further divided into non-vector (no known 
vector), tick-borne and mosquito-borne clusters (Kuno et al., 1998; Vasilakis and Weaver, 
2016). The last subgroup is the largest, and it contains important human pathogens such as 
Dengue virus, West Nile virus, and Yellow fever virus (Kuno et al., 1998; Papageorgiou et 
al., 2016; Vasilakis and Weaver, 2016). 
 
Figure 1. Genera within the Flaviviridae family. 
The evolutionary relationships between the four genera within the Flaviviridae family are 
schematically shown. For each genus, the number of species as well as the type species are 
indicated. Figure adapted from (Kuno et al., 1998).  
 
Mosquito-borne Flaviviruses 
The mosquito-borne Flavivirus cluster contains nine clades numbered VI to XIV (clades I-
III being in the non-vector cluster and clades IV and V being in the tick-borne cluster) 
(Kuno et al., 1998). The evolutionary relationships between these clades are outlined in 
Figure 2. Viruses of public health importance within the mosquito-borne Flavivirus cluster 
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are Yellow Fever virus (YFV), Dengue virus (DENV), Zika virus (ZIKV), Japanese 
encephalitis virus (JEV) and West Nile virus (WNV). Their relationships compared to each 
other are also shown in Figure 2.  
 
Figure 2. Clades within the mosquito-borne Flavivirus cluster. 
The evolutionary relationships between the nine clades within the mosquito-borne 
Flavivirus cluster are schematically shown. Figure adapted from (Kuno et al., 1998).  
 
Over the last decades, the global incidence of mosquito-borne Flaviviruses has grown 
dramatically. For instance, before 1999, WNV was absent in the Americas. However, since 
its introduction in New York 18 years ago, it has rapidly spread over the continent, and 
today it is found in more than 20 countries in the Western hemisphere (Chancey et al., 
2015; Ciota and Kramer, 2013; Elizondo-Quiroga and Elizondo-Quiroga, 2013). The recent 
emergence of ZIKV is another example of increasing Flavivirus prevalence. Until ten years 
ago, only a few isolated cases were reported. The first large Zika outbreak occurred in 2007 
on Yap Island, followed by outbreaks in French Polynesia, Easter Island, Cook Islands and 
New Caledonia in 2013-2014 (WHO, 2017). The most recent epidemic originated in Brazil 
in 2015 and has since then spread to more than 50 countries and territories in Central and 
South America, Africa and the Western Pacific region (WHO, 2017, 2016a). 
 
 
Given that Flaviviruses are widely spread, the majority of the world’s population is 
exposed to at least one of these viruses. In addition, millions of infections occur every year, 
causing thousands of deaths. Current statistics for DENV (WHO, 2016b), YFV (WHO, 
2016c, 2014), WNV (Elizondo-Quiroga and Elizondo-Quiroga, 2013) and JEV (WHO, 
2015) are shown in Table 1.  
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Virus Countries affected Population at risk Clinical cases per year 
Deaths  
per year 
DENV 128 3.9 billion 96 million 12,500 
YFV 47 >900 million 150,000 30,000 
WNV 21 >500 million n/a n/a 
JEV 24 >3 billion 68,000 15,000 
 
Table 1. Current statistics for common mosquito-borne Flaviviruses. 
The number of countries affected, people at risk of infection, clinical cases per year and 
deaths per year due to DENV, YFV, WNV and JEV are shown. Statistics for DENV, YFV 
and JEV include all countries worldwide whereas statistics for WNV include only countries 
in the Americas. Data shown in this table were obtained from (Elizondo-Quiroga and 
Elizondo-Quiroga, 2013; WHO, 2016b, 2016c, 2015, 2014). 
 
Transmission 
The above-mentioned Flaviviruses are transferred to new hosts via female mosquitoes’ 
saliva during blood feeding (Chancey et al., 2015; Colpitts et al., 2012; Weaver and Barrett, 
2004). Culex mosquitoes are the primary vectors of WNV (Chancey et al., 2015; Ciota and 
Kramer, 2013; Colpitts et al., 2012; Weaver and Barrett, 2004; WHO, 2011) and JEV 
(Weaver and Barrett, 2004; WHO, 2015) whereas Aedes mosquitoes are the principal 
vectors of DENV (Vasilakis et al., 2011; Vasilakis and Weaver, 2016; Weaver and Barrett, 
2004; WHO, 2016b), YFV (Vasilakis and Weaver, 2016; Weaver and Barrett, 2004; WHO, 
2016c) and ZIKV (Vasilakis and Weaver, 2016; WHO, 2016d). Transmission cycles and 
hosts vary between Flaviviruses transmitted by different genera of mosquitoes. On the one 
hand, DENV, YFV and ZIKV are maintained in two ecologically and evolutionary 
independent transmission cycles, namely a sylvatic cycle involving arboreal Aedes 
mosquitoes and non-human primates, and an urban cycle involving peridomestic/domestic 
Aedes mosquitoes and humans (Vasilakis et al., 2011; Vasilakis and Weaver, 2016; Weaver 
and Barrett, 2004). These two cycles are connected by some Aedes species that feed on 
both non-human primates and humans, also called bridge vectors (Vasilakis and Weaver, 
2016). On the other hand, the main transmission cycles of JEV and WNV are constituted of 
Culex mosquitoes as vectors and birds as hosts (Chancey et al., 2015; Ciota and Kramer, 
2013; Colpitts et al., 2012; Weaver and Barrett, 2004). Humans and other mammals can be 
infected, but they are dead-end hosts given that their levels of viremia are too low to infect 
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mosquitoes (Chancey et al., 2015; Ciota and Kramer, 2013; Colpitts et al., 2012; Weaver 
and Barrett, 2004). 
 
The increasing global distribution of Flaviviruses is due to multiple factors. Regions that 
are suitable for the survival of the mosquito vectors are expanding to previously unaffected 
zones due to climate change and rising temperatures (Ciota and Kramer, 2013; Vasilakis et 
al., 2011; WHO, 2014). In addition, migratory birds have transported WNV and JEV over 
long distances (Ciota and Kramer, 2013; Weaver and Barrett, 2004). Finally, DENV and 
YFV were probably introduced into the Americas during slave trade when people from 
Central and West Africa, i.e. regions where many Flaviviruses originated, were taken to the 
New World (Vasilakis et al., 2011).    
 
Symptoms 
The majority of Flavivirus infections are asymptomatic (WHO, 2016c, 2015, 2011), and in 
cases that manifest clinically, symptoms vary widely. Most patients experience a flu-like 
illness including fever, headache, muscle and joint pain, nausea, vomiting, and rash (WHO, 
2016b, 2016c, 2016d, 2015, 2011). Severe symptoms such as high fever, seizures, 
encephalitis, paralysis, jaundice (YFV), haemorrhage (DENV and YFV), coma, and 
ultimately death occur only in a small number of cases (WHO, 2016b, 2016c, 2015, 2011). 
Moreover, ZIKV has been linked to microcephaly and Guillain-Barré syndrome (WHO, 
2016d). 
 
Treatment and prevention 
No specific antiviral drugs are available to cure Flavivirus infections, and treatment 
consists of supportive care (WHO, 2016b, 2016c, 2015, 2011). Methods of prevention 
include vector control and vaccination. Safe and effective JEV and YFV vaccines have 
been available for several decades (Erlanger et al., 2009; Sanofi Pasteur, 2016; WHO, 
2016c, 2015). In late 2015, the first DENV vaccine was approved in certain endemic 
countries, and other dengue vaccine candidates are in clinical trials (WHO, 2016b, 2016e). 
WNV vaccines are available for use in horses, but vaccine candidates for humans are still in 
  5
Schematic linear representation of the Flavivirus genome with its 5’ cap structure, 5’ 
and 3’ UTRs, and ORF encoding three structural (orange) and eight non-structural 
(blue) proteins. Figure adapted from (Sampath and Padmanabhan, 2009). 
various stages of (pre)clinical trials (Amanna and Slifka, 2014; WHO, 2011). Due to 
insufficient vaccination coverage for some viruses or the absence of licensed vaccines for 
other viruses, vector control and protection from mosquito bites are crucial for the 
prevention of Flavivirus infections. Eradication of adult mosquitoes using insecticides has 
been successful in the past, but is now considered environmentally unacceptable (Vasilakis 
and Weaver, 2016). Current strategies for reducing mosquito populations include the 
elimination of mosquito breeding sites and larval habitats (Vasilakis and Weaver, 2016; 
WHO, 2016b, 2016c, 2016d), the use of lethal traps, the release of mosquitoes carrying 
Wolbachia bacteria that suppress viral transmission, and the release of genetically modified 
mosquitoes carrying a dominant gene that causes the death of all offspring (Vasilakis and 
Weaver, 2016). Contact between humans and vectors can be reduced by using window 
screens, sleeping under mosquito nets, wearing light colored clothing that covers most of 
the body, and applying insect repellant containing DEET (WHO, 2016b, 2016d, 2011). In 
order to develop effective antiviral drugs to treat infection and reduce the number of 
fatalities, the molecular mechanisms of Flaviviruses need to be well understood and 
characterized. 
 
Flavivirus genome and proteins 
The Flavivirus genome is a single-stranded RNA (ssRNA) (Stollar et al., 1966; Wengler et 
al., 1978) of positive polarity (Stollar et al., 1967; Wengler et al., 1978) and approximately 
11kb in length (Castle et al., 1986; Rice et al., 1985; Sumiyoshi et al., 1987). In addition to 
a single open reading frame (ORF), it contains 5’ and 3’ untranslated regions (UTRs) (Rice 
et al., 1985; Sumiyoshi et al., 1987). It harbors a 5’ type I cap structure (Wengler et al., 
1978), and it is not polyadenylated at the 3’ terminus (Wengler et al., 1978; Wengler and 
Wengler, 1981). 
 
Figure 3. Flavivirus genome and viral proteins. 
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The viral genome also serves as viral mRNA for the translation of the ORF into a large 
polyprotein (Boulton and Westaway, 1977; Naeve and Trent, 1978) that is co- and post-
translationally processed into three structural (C, prM or M, E) (Rice et al., 1985; Shapiro 
et al., 1971; Stollar, 1969; Trent and Qureshi, 1971) and eight non-structural (NS1, NS2A, 
NS2B, NS3, NS4A, 2K, NS4B, NS5) proteins (Rice et al., 1985; Sumiyoshi et al., 1987). 
An outline of the Flavivirus genome and proteins is shown in Figure 3.  
 
Structural proteins 
The structural proteins are components of virus particles. They are involved in virus entry 
into the host cell as well as assembly and release of new virions. The envelope (E) and 
membrane (M) glycoproteins are inserted into the lipid envelope of mature viruses, and the 
capsid (C) protein forms the capsid that encloses the viral RNA genome (Kaufmann and 
Rossmann, 2011; Lindenbach et al., 2007; Mukhopadhyay et al., 2005). 
 
Non-structural proteins 
Only two of the eight non-structural proteins are known to possess enzymatic activities, 
namely NS3 and NS5. Both proteins contain two domains and multiple functions. NS3 is a 
serine protease (Chambers et al., 1990b; Preugschat et al., 1990; Wengler et al., 1991), 
RNA helicase (Li et al., 1999; Utama et al., 2000), nucleoside triphosphatase (NTPase) 
(Takegami et al., 1995; Warrener et al., 1993; Wengler and Wengler, 1991), and RNA 
triphosphatase (RTPase) (Bartelma and Padmanabhan, 2002; Wengler and Wengler, 1993). 
NS5 is a methyltransferase (MTase) (Egloff et al., 2002; Ray et al., 2006), 
guanylyltransferase (GTase) (Issur et al., 2009), and RNA-dependent RNA polymerase 
(RdRp) (Guyatt et al., 2001; Tan et al., 1996). Together, they form the RNA replicase 
complex. Besides their enzymatic activities during viral replication, NS3 and NS5 also 
accomplish other non-enzymatic functions. NS3 is involved in virus assembly (Kümmerer 
and Rice, 2002; Patkar and Kuhn, 2008), and NS5 participates in the evasion of the 
immune response by blocking interferon (IFN) signaling (Ashour et al., 2009; Laurent-
Rolle et al., 2010). 
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The other non-structural proteins assume various roles to support viral replication and to 
evade or modulate the host cell’s immune response. NS1 has various functions depending 
on its oligomerization state and cellular localization. The intracellular NS1 dimer is 
involved in viral genome replication, most likely by stabilizing the association between the 
replication complex and membranes (Mackenzie et al., 1996; Muller and Young, 2013; 
Muylaert et al., 1996). The secreted NS1 hexamer interacts with a wide range of host cell 
components, engages with both the innate and adaptive immunity and elicits both a 
protective and pathogenic immune response (Muller and Young, 2013). NS2A (Xie et al., 
2013), NS2B (Li et al., 2015), NS4A (Miller et al., 2007; Nemésio et al., 2012), 2K (Miller 
et al., 2007) and NS4B (Miller et al., 2006; Nemésio et al., 2012) are small proteins 
containing multiple transmembrane domains. They have been shown to be part of the viral 
replication complex that is located within replication compartments derived from the 
endoplasmic reticulum (ER) membrane (Mackenzie et al., 1998; Welsch et al., 2009). 
NS2A participates in the production of infectious virus particles (Kümmerer and Rice, 
2002; Liu et al., 2003; Xie et al., 2013), in the induction of membrane rearrangements 
(Leung et al., 2008), and in the evasion of the cellular antiviral response by inhibiting the 
IFN signaling pathway (Liu et al., 2004; Muñoz-Jordán et al., 2003; Tu et al., 2012). NS2B 
serves as an essential cofactor for the NS3 protease (Chambers et al., 1991; Falgout et al., 
1991). NS4A induces ER membrane rearrangements during the formation of the viral 
replication compartment (Miller et al., 2007; Roosendaal et al., 2006), acts as a cofactor for 
the NS3 helicase activity (Shiryaev et al., 2009), and participates in immune evasion 
through the inhibition of IFN signaling (Muñoz-Jordán et al., 2003). 2K is often considered 
part of the NS4A protein, although it has been shown to serve as signal peptide required for 
the translocation and the correct insertion of NS4B into the ER membrane (Lin et al., 1993; 
Muñoz-Jordán et al., 2005). Moreover, it has been proposed to be involved in viral 
replication through membrane rearrangements or evasion of the immune response (Zou et 
al., 2009). NS4B serves as a cofactor for the NS3 helicase activity (Umareddy et al., 2006), 
and it is the main viral protein that inhibits the IFN α/β signaling pathway (Muñoz-Jordán 
et al., 2003). It has also been proposed to be a mediator of cell death (Evans and Seeger, 
2007).  
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Flavivirus life cycle 
Flaviviruses enter host cells through receptor-mediated endocytosis which is triggered by 
the binding of the envelope (E) protein to receptors and attachment factors on the surface of 
the host cell (Kaufmann and Rossmann, 2011; Perera-Lecoin et al., 2013). Receptor 
recognition and attachment has been proposed to involve multiple molecules in 
combination or consecutively, although the identity of these molecules remains elusive. 
Glycosaminoglycans have been suggested to act as attachment factors that concentrate 
virus particles on the cell surface before receptor-mediated internalisation. Calcium-
dependent lectin receptors, αvβ3 integrin as well as phosphatidylserine, TIM (T-cell 
immunoglobulin and mucin domain) and TAM (Tyro3, Axl, Mer) receptors have been 
described as candidate receptors for different Flaviviruses in different cell types, but their 
precise role in virus endocytosis remains to be determined (Kaufmann and Rossmann, 
2011; Perera-Lecoin et al., 2013). Following endocytosis, the acidic environment in the late 
endosome causes the E protein to undergo a conformational change and to trimerize, 
resulting in the fusion of the viral and endocytic membranes and the release of the 
nucleocapsid core into the cytoplasm (Kaufmann and Rossmann, 2011; Stiasny et al., 
2011). After dissociation of the viral RNA from the capsid (C) protein, translation of the 
viral genome into the viral polyprotein takes place on the rough ER (Stohlman et al., 1975). 
Signal sequences within prM, E and NS1 cause the translocation of these parts of the 
polyprotein into the ER lumen (Perera and Kuhn, 2008). The transmembrane domains of 
NS2A, NS2B, NS4A, 2K and NS4B are inserted into the ER membrane whereas C, NS3 
and NS5 stay in the cytoplasm (Lindenbach et al., 2007; Perera and Kuhn, 2008). Cleavage 
of the polyprotein into separate viral proteins is achieved by the viral NS2B-NS3 protease 
in the cytoplasm and by host signalases inside the ER lumen (Perera and Kuhn, 2008). 
Polyprotein translocation and processing occurs co- and post-translationally (Lindenbach et 
al., 2007). Once synthesized, the viral proteins assume their respective functions to initiate 
replication of the viral genome. The formation of vesicles, also called replication 
compartments since they are the site of viral genome replication, is induced (Uchil and 
Satchidanandam, 2003; Welsch et al., 2009). These vesicles are derived from the ER 
membrane (Gillespie et al., 2010; Miller et al., 2007, 2006; Paul and Bartenschlager, 2013; 
Welsch et al., 2009) and they are connected to the cytoplasm through a small pore 
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(Gillespie et al., 2010; Paul and Bartenschlager, 2013; Welsch et al., 2009). They protect 
viral proteins and RNA from proteases and nucleases (Paul and Bartenschlager, 2013; 
Uchil and Satchidanandam, 2003) as well as antiviral activity of IFN-stimulated proteins 
(Hoenen et al., 2007), and they ensure high efficacy of replication by concentrating all 
necessary components to these structures (Paul and Bartenschlager, 2013). The single-
stranded, positive sense genomic RNA is first transcribed into negative sense RNA, 
resulting in a double stranded RNA (dsRNA) which is also referred to as replicative form 
RNA. Negative strand synthesis relies primarily on the NS5 RdRp, and NS3 does not seem 
to be strictly necessary. The dsRNA then serves as the template for the synthesis of a large 
number of capped (+)ssRNA viral genomes. Positive strand synthesis is a much more 
complex process which requires dsRNA unwinding and is coupled to positive strand 
capping, and thus involves the replication complex composed of the NS3 helicase domain 
and both domains of the NS5 protein (Saeedi and Geiss, 2013). The newly generated viral 
genomic RNA molecules are released from the replication compartments and used for 
multiple purposes (Miorin et al., 2013; Saeedi and Geiss, 2013). Some of the nascent 
genomic RNAs localize to the rough ER for further translation and synthesis of viral 
proteins. Others seem to be directed toward P-bodies for partial degradation and thus 
creation of subgenomic flavivirus RNA (sfRNA), a noncoding RNA derived from the 3’ 
UTR of the viral genomic RNA that promotes virus replication, cytopathicity and 
pathogenicity (Funk et al., 2010; Pijlman et al., 2008). Finally, some of the new viral RNA 
genomes interact with capsid proteins to form nucleocapsids in the cytoplasm. These bud 
into the ER lumen through the ER membrane containing prM and E glycoproteins, thus 
forming immature virus particles (Lindenbach et al., 2007). Budding occurs in close 
proximity to the neck of replication compartments, limiting the exposure of viral RNA to 
host cell nucleases and sensors of the innate immune response and suggesting that 
replication and assembly are coordinated (Welsch et al., 2009). While transiting the trans-
Golgi network, the E protein undergoes conformational changes and the prM protein is 
cleaved into the mature M protein (Perera and Kuhn, 2008). Mature, infectious virus 
particles are finally released by exocytosis (Lindenbach et al., 2007; Suthar et al., 2013). 
Subviral particles are also assembled in the ER and released the same way as infectious 
virions (Mukhopadhyay et al., 2005). However, they only contain a lipid envelope and the 
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two glycoproteins E and M, but no nucleocapsid, and are therefore non-infectious 
(Mukhopadhyay et al., 2005; Schalich et al., 1996). These particles, which are also known 
as defective interfering particles, possess hemagglutination activity and could act as decoys 
to help confuse the immune system (Heinz and Allison, 2000). The Flavivirus life cycle is 
graphically summarized in Figure 4. 
 
 
 
Figure 4. Flavivirus life cycle. 
Schematic representation of the viral life cycle. The virus enters the host cell through 
receptor-mediated endocytosis (1) which is followed by release of the viral genome into the 
cytoplasm (2). This RNA is translated into viral proteins at the rough ER (3). The non-
structural proteins form the replication complex that produces a large number of new viral 
genomes (4). These genomes are associated with capsid proteins to form nucleocapsids (5) 
that bud into the ER containing the other structural proteins (6). The nascent virions 
undergo maturation in the trans-Golgi network (7) and are released from the host cell 
through exocytosis (8). Figure adapted from (Suthar et al., 2013). 
 
 
Viral RNA replication is a major process during the viral life cycle. Negative strand 
synthesis by the NS5 RdRp has been extensively studied and is well understood. However, 
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there is little information about the mechanisms of positive strand synthesis involving the 
replicase complex constituted of NS3 and NS5 (Saeedi and Geiss, 2013). 
 
Flavivirus replicase complex 
The replicase complex responsible for positive strand RNA synthesis during Flavivirus 
infection comprises mainly the two viral enzymes NS3 and NS5 (Klema et al., 2015).  
 
Non-structural protein 3 
Non-structural protein 3 (NS3) is the second largest and the second most conserved 
Flavivirus protein. In fact, NS3 proteins from WNV, DENV, JEV, ZIKV and YFV share 
approximately 65% sequence identity on the amino acid level (Appendix 1). The NS3 
protein contains two domains that are coupled via a short flexible linker, namely an N-
terminal protease domain and a C-terminal helicase domain (Figure 5) (Luo et al., 2008a). 
Whereas some studies suggest that the activities of the two domains are independent from 
one another (Assenberg et al., 2009; Gebhard et al., 2012), most studies indicate a 
functional coupling between the two domains (Luo et al., 2010, 2008a; Mastrangelo et al., 
2007; Xu et al., 2006, 2005).  
 
NS3 structures 
Both individual domains as well as full-length NS3 proteins from multiple Flaviviruses 
have been crystallized and their three-dimensional structures have been resolved (Appendix 
2). Different conformations of the full-length proteins with different relative orientations of 
the two domains have been reported (Luo et al., 2010, 2008a). These findings indicate that 
there is flexibility between the two domains, and that different conformational states could 
exist in vivo. In fact, RNA binding has been suggested to trigger conformational change in 
NS3 (Benzaghou et al., 2006; Luo et al., 2008b).  
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Figure 5. Crystal structure of the NS3 protein. 
Full-length NS3 from DENV, pdb 2vbc (Luo et al., 2008a). [A] The protease (NS3 1-168 
and NS2B 49-63) is colored in green, the inter-domain linker (169-179) in gray, and the 
helicase domain (180-618) in orange. [B] The protease domain (1-168) is colored in green, 
the NS2B cofactor (49-63) in pale green, the inter-domain linker (169-179) in gray, the 
helicase subdomain 1 (180-326) in yellow, the helicase subdomain 2 (327-481) in orange, 
and the helicase subdomain 3 (482-618) in red. Boundaries of the linker region and the 
helicase subdomains are based on reports by (Luo et al., 2010) and (Luo et al., 2008b), 
respectively. 
 
NS3 protease domain 
The protease domain is located in the N-terminal third of NS3 (Chambers et al., 1990b; 
Preugschat et al., 1990; Wengler et al., 1991). It contains four regions of homology with 
serine proteases, three of which comprise residues of the catalytic triad H51-D75-S135 
(DENV numbering) (Bazan and Fletterick, 1989; Gorbalenya et al., 1989). This triad is 
strictly conserved among Flaviviruses and it is located in a cleft between two β-barrels 
(Erbel et al., 2006). The fourth region of homology with serine proteases is part of the 
substrate binding pocket which includes residues D129, F130, Y150, N152 and G153 
(DENV numbering) (Bazan and Fletterick, 1989; Valle and Falgout, 1998). The aspartic 
acid residue at the bottom of the binding pocket has been suggested to be responsible for 
the specificity for cleavage sites that generally contain two basic residues followed by a 
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residue with a small side chain like G(A)RRS (Chambers et al., 1990a, 1990b), although 
the exact sequence varies between cleavage sites and viruses (Yotmanee et al., 2015). 
Sequences at which NS3 cleaves the viral polyprotein are located at the NS2A/NS2B, 
NS2B/NS3, NS3/NS4A, NS4A/2K and NS4B/NS5 junctions (Chambers et al., 1991; Lin et 
al., 1993). In addition, cleavage of the C-terminal membrane-spanning segment of the C 
protein, which occurs after several basic residues, is mediated by NS3 (Lobigs, 1993). 
 
The cytoplasmic portion of the NS2B protein is essential for the formation of an active 
NS2B-NS3 protease (Chambers et al., 1993). Residues 53-58 (WNV numbering) form a β-
strand which stabilizes the NS3 protease structure by folding into its N-terminal β-barrel 
(Erbel et al., 2006). Residues 64-96 of NS2B (WNV numbering) wrap around NS3, and 
upon substrate binding, residues 78-87 undergo a conformational change to form a 
stabilizing β-hairpin that becomes part of the protease active site (Aleshin et al., 2007; 
Erbel et al., 2006).  
 
NS3 helicase domain 
In addition to helicase activity, the C-terminal helicase domain of NS3 also harbors 
nucleoside triphosphatase (NTPase) and RNA triphosphatase (RTPase) activities (Li et al., 
1999; Wengler and Wengler, 1993, 1991). NTPase and RTPase reactions occur in the same 
active site (Bartelma and Padmanabhan, 2002; Benarroch et al., 2004b; Sampath et al., 
2006) whereas dsRNA unwinding, although driven by ATP hydrolysis, takes place at a 
distinct site known as helical gate (Mastrangelo et al., 2012). The RTPase reaction removes 
the γ-phosphate from the newly synthesized viral RNA to form a diphosphorylated RNA 
and thus constitutes the first step in the synthesis of the 5’ cap structure (Wengler and 
Wengler, 1993). The RNA helicase activity unwinds the dsRNA replication intermediate to 
make the negative strand available as template for further genome replication and to release 
the positive strand for translation of viral proteins or packaging into virions, and it disrupts 
secondary structures in the viral RNA which are found especially in the 5’ and 3’ UTRs (Li 
et al., 2014; Luo et al., 2015). The unwinding of these structures is important for assembly 
of the replicase complex at the 3’ end and an efficient RTPase reaction at the 5’ end (Wang 
et al., 2009). As mentioned above, the helicase activity is driven by the energy released 
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from the hydrolysis of the γ-phosphate of nucleoside triphosphates, especially ATP and 
GTP, but how these two activities are coupled remains elusive (Li et al., 1999; Luo et al., 
2015). 
 
Figure 6. NS3 helicase domain bound to ssRNA. 
NS3 helicase domain from DENV in complex with ssRNA, pdb 2jlu (Luo et al., 2008b). 
Subdomains 1 (168-326), 2 (327-481) and 3 (482-618) are colored in yellow, orange and 
red, respectively. The NTPase/RTPase active site, the helical gate as well as the 5’ and 3’ 
ends of the ssRNA are indicated. 
 
The NS3 helicase domain is further divided into three subdomains (Figure 6). Seven 
conserved helicase motifs characteristic of superfamily 2 helicases, including Walker A and 
Walker B motifs, are contained in subdomains 1 and 2 (Mastrangelo et al., 2007; Wu et al., 
2005; Xu et al., 2005). The ssRNA binding tunnel is located between subdomains 1 and 2 
on one side and subdomain 3 on the other side (Luo et al., 2008b), and the helical gate 
formed by α-helix 2 of subdomain II, α-helix 6 of subdomain III and a β-hairpin protruding 
from subdomain II toward subdomain III constitutes the entry site to this groove 
(Mastrangelo et al., 2012). In fact, the β-hairpin acts as a helix opener by disrupting base 
stacking between the two strands of dsRNA so that the 3’ end of the negative strand enters 
the RNA binding tunnel whereas the 5’ end of the positive strand is forced to move along 
the protein’s surface (Luo et al., 2015, 2008b). The RNA unwinding site is at a distance of 
about 30Å from the catalytic site where ATP is hydrolyzed (Mastrangelo et al., 2012), and 
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the exact mechanism by which these two events are coupled remains elusive (Li et al., 
2014; Luo et al., 2015). The NTPase / RTPase active site is a basic pocket near the interface 
between the helicase and protease domains (Luo et al., 2008a). Substrate binding and 
coordination of a magnesium ion are mediated by residues from the Walker A and Walker 
B motifs, respectively (Assenberg et al., 2009; Benarroch et al., 2004b; Mastrangelo et al., 
2007). Moreover, residues R457, R458, R460 and R463 (DENV numbering) which are 
located close to the active site have been shown to be crucial for both activities (Sampath et 
al., 2006). The exit channel for the phosphate product of the NTPase and RTPase reactions 
has been proposed to be formed by residues P195, A316, T317, P326, A455 and Q456 
(DENV numbering) (Luo et al., 2008b). 
 
Enzymatic activities of the NS3 helicase domain are influenced by the presence of other 
macromolecules. Binding of ssRNA to residues R184, K185, R186 and K187 (DENV 
numbering) has been shown to stimulate NTPase activity (Li et al., 1999; Warrener et al., 
1993; Yon et al., 2005). Moreover, both NTPase and RTPase activities have been shown to 
be enhanced by the presence of NS5 (Cui et al., 1998; Yon et al., 2005). Finally, NS4A and 
NS4B are cofactors for the NS3 helicase activity: NS4A binds to the helicase domain and 
reduces the amount of ATP required for the unwinding of dsRNA (Shiryaev et al., 2009), 
whereas NS4B interacts with subdomains 2 and 3 (Zou et al., 2015a) and facilitates 
dissociation of NS3 from ssRNA (Umareddy et al., 2006). 
 
Non-structural protein 5 
Non-structural protein 5 (NS5) is the largest Flavivirus protein with approximately 103kDa. 
It is also the most conserved Flavivirus protein with a sequence identity of approximately 
68% between WNV, DENV, JEV, ZIKV and YFV (Appendix 3). Like the other viral 
enzyme NS3, NS5 contains two domains that are connected via a short linker, namely an 
N-terminal capping enzyme domain and a C-terminal RNA-dependent RNA polymerase 
domain (Figure 7) (Lu and Gong, 2013). 
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NS5 structures 
The three-dimensional structures of both domains and the full-length proteins from 
different Flaviviruses have been determined (Appendix 4). Conformations varying from a 
rather compact structure to a more extended structure have been reported, suggesting 
flexibility in the relative orientation of the two domains and the possibility of different 
conformational states for NS5 (Bussetta and Choi, 2012; Lu and Gong, 2013; Zhao et al., 
2015b). Since the inter-domain linker is well-ordered in some crystal structures but without 
secondary structure in others, it seems to play a central role in the adoption of different 
conformations (Lu and Gong, 2013; Zhao et al., 2015b). Furthermore, residues G263-T264-
R265 which are in close proximity to the linker region have been suggested to be a pivot 
point between the two domains and may contribute to conformational changes within the 
protein (Lu and Gong, 2013).  
 
Figure 7. Crystal structure of the NS5 protein. 
Full-length NS5 from JEV, pdb 4k6m (Lu and Gong, 2013). The MTase (1-266) domain is 
colored in blue, the inter-domain linker (267-275) in gray, and the RdRp (276-905) in red. 
Note that three residues from the linker region were unresolved in the structure and are 
represented by a dashed line.  
 
NS5 capping enzyme domain 
The NS5 N-terminal capping enzyme domain is involved in synthesizing the cap structure 
at the 5’ end of the viral genome. It first executes its GTase activity by transferring a GMP 
to the 5’ diphosphate end of nascent viral RNA (Issur et al., 2009). It then carries out its 
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MTase activity using S-adenosyl-L-methionine (SAM) as a methyl donor, and methyl 
groups are transferred to the N7 position of the guanine as well as the 2’-O position of the 
first nucleotide’s ribose (Egloff et al., 2002; Ray et al., 2006). Since the NS5 capping 
enzyme domain mediates two different kinds of enzymatic reactions using different 
substrates, it has two distinct substrate binding pockets which are separated by a positively 
charged surface groove of 12-15Å (Figure 8). This region is believed to bind viral RNA 
during the GTase and MTase reactions (Egloff et al., 2007, 2002; Geiss et al., 2009; Zhou 
et al., 2007). The entry site of the 5’ diphosphorylated RNA (ppRNA) into the capping 
enzyme has been suggested to be the groove between helices A2 and A3, given that 
residues F25, K30, R57, K181 and R212 (DENV numbering), which are clustered around 
the base of helix A2, have been shown to bind ppRNA (Henderson et al., 2011). 
Interestingly, some of the residues involved in ppRNA binding are also involved in GTP 
binding. In fact, the GTP binding pocket includes K14, L17, N18, L20, F25, K29 and S150 
(DENV numbering), and this pocket is believed to be the active site for the GTase activity 
(Egloff et al., 2007, 2002). The fact that the phosphates of GTP and the phosphates of 
ppRNA compete for the same binding site on the capping enzyme suggests that they are 
bound at different times during the guanylyltransferase reaction. GTP is bound first to form 
a GMP-enzyme intermediate, and then ppRNA is bound for the transfer of GMP to the 
RNA, resulting in a GpppRNA product (Henderson et al., 2011; Issur et al., 2009). This 
basic cap structure then undergoes two methyltransferase reactions to form completely 
capped m7GpppNmRNA. Both MTase reactions occur at the catalytic tetrad K61-D146-
K181-E217 (DENV numbering) (Ray et al., 2006) near the SAM binding pocket which 
includes residues S56, G86, W87, T104, L105, D131, V132, I147 and Y219 (DENV 
numbering) (Egloff et al., 2002), and N7-methylation precedes 2’-O-methylation (Ray et 
al., 2006; Zhou et al., 2007). The RNA substrate needs to be repositioned between the two 
MTase reactions, and the RNA cap structure has been suggested to be bound to the GTP 
binding pocket during 2’-O-methylation (Zhou et al., 2007). 
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Figure 8. NS5 capping enzyme domain bound to GTP and SAH. 
NS5 capping enzyme domain from YFV in complex with GTP and SAH, pdb 3evd (Geiss 
et al., 2009). [A] Cartoon representation. [B] Surface representation. The ppRNA entry site 
between helices A2 and A3 as well as the GTP and SAM binding pockets are shown.  
 
NS5 RNA-dependent RNA polymerase domain 
Replication of the viral RNA genome takes place in the NS5 C-terminal RNA-dependent 
RNA polymerase (RdRp) domain (Selisko et al., 2006; Tan et al., 1996). This domain has 
an approximately spherical shape and adopts the canonical right-hand conformation with 
fingers, palm and thumb subdomains (Figure 9). The palm subdomain contains five of the 
seven catalytic motifs (A through E) that are conserved among all viral RdRps whereas the 
two other motifs (F and G) are located in the fingers subdomain (Malet et al., 2007; Yap et 
al., 2007). The catalytic active site is situated within the palm subdomain near the interface 
with the fingers and thumb subdomains. In fact, it is encircled by the fingertips that mediate 
the interaction between the fingers and thumb subdomains (Malet et al., 2007; Yap et al., 
2007). This structure also constitutes the RNA binding tunnel through which the template 
RNA gains access to the active site (Yap et al., 2007). A second tunnel between the fingers 
and palm domain, which goes across the entire protein and is approximately perpendicular 
to the first one, also connects to the active site (Malet et al., 2007). The back of this channel 
serves as entry site for NTPs, and the dsRNA product would exit the RdRp domain through 
the front of this channel (Choi and Rossmann, 2009; Malet et al., 2007). However, in all 
observed structures, the RdRp domain is in a closed conformation in which the C-terminal 
motif of the thumb subdomain blocks this exit site, and a conformational change to an open 
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state during elongation would be required to accommodate nascent dsRNA in this channel 
(Choi and Rossmann, 2009; Malet et al., 2007). 
 
 
Figure 9. NS5 RdRp domain. 
NS5 RdRp domain from WNV, pdb 2hfz (Malet et al., 2007). [A] Cartoon representation. 
[B] Surface representation. The fingers subdomain (274-498, 542-609) is colored in red, the 
palm subdomain (499-541, 610-717) in orange, the thumb subdomain (718-905) in yellow, 
and the priming loop (796-809) in purple. The aspartic acids (536 and 669) that coordinate 
the catalytic magnesium ions are shown as magenta colored sticks. The RNA template 
channel is between the fingers and thumb subdomain. NTPs enter the active site through a 
second channel from the back of the RdRp domain. 
 
The NS5 RdRp performs de novo RNA synthesis (Ackermann and Padmanabhan, 2001), 
and several structural elements have been found to play an important role in initiation. The 
priming loop (residues 782-809, DENV numbering) protrudes from the thumb subdomain 
toward the active site in the palm domain and thus partially occludes the template RNA 
tunnel, allowing only ssRNA to access the active site (Choi and Rossmann, 2009; Yap et 
al., 2007). Moreover, it contains two conserved residues, W795 and H798 (DENV 
numbering) that provide an initiation platform by forming stacking interactions with 
nucleotides during de novo initiation (Selisko et al., 2012; Yap et al., 2007). The initiating 
ATP molecule is stacked against H798 (Selisko et al., 2012) whereas W795 stabilizes a 
GTP molecule at the de novo GTP-binding site (or i-1 position) which is 6-7Å from the 
catalytic motif (Choi and Rossmann, 2009; Noble and Shi, 2012). This special GTP is 
crucial for initiation, since de novo RNA synthesis has been shown to require a high 
concentration of GTP regardless of the nucleotide sequence at the 3’ terminus of the 
template RNA (Nomaguchi et al., 2003). The GTP molecule has been proposed to stabilize 
the initiating ATP at the i position and to contribute to the proper positioning of its 3’ 
hydroxyl group for the nucleophilic attack that results in the formation of a phosphodiester 
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bond with the second nucleotide at the i+1 position (Choi and Rossmann, 2009). During 
this reaction, the phosphates of the incoming nucleotide are held in place by two Mg2+ ions 
that are coordinated by D533 and D664 (DENV numbering) (Choi and Rossmann, 2009; 
Malet et al., 2007; Yap et al., 2007). Once the initiating dinucleotide is synthesized, GTP is 
released and the RdRp switches to an open conformation to allow elongation of the nascent 
dsRNA (Choi and Rossmann, 2009). The mechanism of translocation of the RdRp along 
the template RNA still remains elusive, although motif G of the fingertip region has been 
proposed to play a role in this process (Choi and Rossmann, 2009; Wu et al., 2015).  
 
Interactions among non-structural proteins 
Given that the replicase complex is formed by non-structural proteins 3 and 5 and that its 
function is supported by some of the other viral proteins, there are multiple interactions 
among the non-structural proteins. The central hydrophilic region of NS2B, which is 
located in the cytoplasm, interacts with the NS3 protease domain to fulfill its role as 
essential cofactor (Aleshin et al., 2007; Erbel et al., 2006). NS4A and NS4B are cofactors 
for the helicase activity of NS3 and therefore interact with the NS3 helicase domain 
(Shiryaev et al., 2009; Umareddy et al., 2006; Zou et al., 2015a). Since NS2B, NS4A and 
NS4B possess transmembrane regions in addition to regions that interact with NS3, they 
anchor the replicase complex to the ER membrane (Li et al., 2015; Miller et al., 2007, 
2006). Moreover, NS4B and NS4A interact with each other, and NS4B also interacts with 
NS1 (Chatel-Chaix et al., 2015). NS5 does not interact with any small transmembrane non-
structural protein, and it is recruited to the membrane-associated replication complex only 
via its interaction with NS3 (Klema et al., 2015).  
 
NS3:NS5 interaction 
The interaction between NS3 and NS5 has been shown by multiple techniques (Brooks et 
al., 2002; Chen et al., 1997; Cui et al., 1998; Johansson et al., 2001; Kapoor et al., 1995; 
Moreland et al., 2012; Takahashi et al., 2012; Tay et al., 2015; Vasudevan et al., 2001; Yu 
et al., 2013; Zou et al., 2011). No other viral protein has been found to be required, 
suggesting that NS3 and NS5 interact directly (Kapoor et al., 1995). The NS3:NS5 
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interaction is believed to be mediated by the NS5 RdRp domain (Brooks et al., 2002; 
Johansson et al., 2001; Moreland et al., 2012; Tay et al., 2015; Vasudevan et al., 2001) and 
the NS3 helicase domain (Johansson et al., 2001; Moreland et al., 2012), although some 
studies also suggest the contribution of the NS3 protease domain (Takahashi et al., 2012; 
Zou et al., 2011). A schematic model of this interaction has been proposed, and the 
interaction between NS3 and NS5 is suggested to be mediated by the NS3 helicase 
subdomain III and the NS5 RdRp thumb subdomain (Tay et al., 2015). However, data from 
this study is questionable because the SAXS data presented is severely biased by the 
artificial covalent fusion of the NS5 320-341 peptide to the C-terminus of the helicase 
subdomain III via a short linker, and conclusions drawn from the experiments might not be 
correct. Moreover, the model focusses on proteins only, and it fails to consider RNA as a 
component of the replicase complex. Further studies including both proteins as well as the 
replicative form of viral RNA are needed to elucidate the interactions between NS3 and 
NS5 within the Flavivirus RNA replicase complex during positive strand synthesis. 
 
Rationale and hypothesis 
Considering that viral replication requires the enzymatic activities of both NS3 and NS5 
proteins, they have been shown to interact, and they most likely coordinate their respective 
activities during positive strand RNA synthesis, it is reasonable to hypothesize that the 
NS3:NS5 interaction within the replicase complex is essential for an efficient viral 
replication. In that case, this interaction could be an interesting target for the development 
of antiviral therapeutics. In the first place, however, the NS3:NS5 interaction needs to be 
well characterized and its precise role in viral replication needs to be elucidated. 
 
Goals 
#1: Develop a model of the interactions between NS3, NS5 and viral RNA as they would 
occur within the WNV replicase complex during positive strand synthesis, and determine 
the amino acid residues on both proteins that mediate the NS3:NS5 interaction. 
#2: Introduce point mutations of the above-determined residues into the NS3 and NS5 
coding sequences in expression vectors, express and purify recombinant NS3 and NS5 
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proteins (wild-type and mutant), and measure their interaction in vitro in the presence and 
absence of RNA. This will help validate the NS3:NS5 interaction model developed in 
silico. 
#3: Introduce point mutations of the above-determined residues into a WNV replicon and 
evaluate the effect of these mutations on viral replication. These replicon assays will help 
validate the biochemical interaction assays and characterize the NS3:NS5 interaction in a 
more complex cellular environment.  
 
 
MATERIALS AND METHODS 
NS3:NS5 interaction model 
An interaction model between NS3, NS5 and a single-stranded RNA was developed based 
on data already available in the literature, such as the crystal structures of the individual 
proteins, locations of active sites and known RNA-binding regions on both proteins. 
Homology structures of the full-length African Lineage II WNV proteins were generated on 
the Swissmodel Server (Arnold et al., 2006) using DENV NS3 (pdb 2vbc) and JEV NS5 
(pdb 4k6m) as structure templates. The single-stranded RNA molecule was 20 nucleotides 
in length and had the random sequence GGUCAGUGUAACAACUGACC. The three 
macromolecules were then imported into Sculptor 2 (Wahle and Wriggers, 2015), a 
structural modeling program primarily used for fitting protein structures into low-resolution 
density maps. Manual docking was performed to generate a model representing interactions 
between NS3, NS5 and ssRNA within the replication complex during positive strand RNA 
synthesis. 
 
Molecular dynamics simulations 
In order to improve the interaction model generated by manual docking, it was subjected to 
molecular dynamics (MD) simulations using NAMD (Phillips et al., 2005). However, 
before starting the MD simulation, the interaction model was slightly modified. RNA was 
removed from the complex, and the full-length NS3 protein was replaced with the NS3 
helicase domain bound to ssRNA (pdb 2jlu served as template for the homology structure 
of WNV NS3). This modified interaction model was developed with PyMOL (Schrödinger, 
LLC). So far, MD simulations have been carried out with the modified interaction model 
containing the two proteins only, in the absence of RNA. If an RNA molecule were 
included in the simulation, it would have to be actively pulled towards the RdRp catalytic 
site during the simulation to bring the proteins into a stable complex and to simulate protein 
translocation along the RNA, thus making the simulation much more complex. Moreover, 
by performing the simulation without RNA at first and with RNA later on, it will be 
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possible to compare the evolution of the complex and to determine if the RNA is important 
for retaining the overall structure of the replicase complex.  
 
The dynamical evolution of the NS3:NS5 complex was monitored by exporting structures 
of the interaction model after various time points in the simulation and visual analysis of 
interaction distances between amino acid side chains between the NS3 and NS5 proteins 
was accomplished. 
 
Recombinant proteins 
Molecular cloning 
The coding sequences of NS3 and NS5 were amplified from an African Lineage II West 
Nile replicon (Pierson et al., 2006) and cloned into bacterial expression vectors pET21b and 
pET28a, respectively. NS3 was fused in-frame with residues 49-66 of NS2B at its N-
terminus as well as an HA-tag and a 6His-tag at its C-terminus whereas NS5 was fused in-
frame with a 6His-tag at its N-terminus. In these contexts, expression of tagged proteins is 
driven by a T7 RNA polymerase promoter. 
 
Protein expression 
The plasmids pET21b-NS2B49-66-NS3 and pET28a-NS5 were transformed into E. coli 
BL21(DE3) and E. coli Rosetta2(DE3)pLysS cells, respectively. 1L cultures of 
BL21(DE3)/pET21b-NS2B49-66-NS3 and Rosetta2(DE3)pLysS/pET28a-NS5 were grown at 
37°C in LB medium containing the appropriate selective antibiotic (100µg/ml ampicillin or 
30µg/ml kanamycin, respectively) until the OD600 reached 0.5. The cultures were then 
incubated on ice for 30min. IPTG (BioShop, IPT001) and ethanol were added to final 
concentrations of 0.4mM and 2%, respectively, and the cultures were incubated at 18°C for 
20h. Cells were harvested by centrifugation at 5000rpm for 10min in a Sorvall SLA-1500 
rotor.  
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Protein purification 
All procedures were performed at 4°C. Pelleted bacteria were resuspended in 30ml 
resuspension buffer (50mM Tris-HCl pH 7.5, 400mM NaCl, 10% sucrose, 25mM 
imidazole), and cells were lysed by adding lysozyme and Triton X-100 to final 
concentrations of 50µg/ml and 0.1%, respectively. The lysates were sonicated (2min, 5sec 
pulse on, 5sec pulse off) and insoluble material was removed by centrifugation at 
10,000rpm for 45min in a Sorvall SS-34 rotor.  
 
The soluble extract was applied to a 5ml HisTrap HP column (GE Healthcare, 17-5248-01) 
previously equilibrated with 25ml buffer A (50mM Tris-HCl pH 7.5, 400mM NaCl, 10% 
sucrose, 0.1% Triton X-100, 25mM imidazole) and connected to an ÄKTA Pure FPLC 
system (GE). The column was washed with 50ml buffer A, and proteins were eluted with a 
25ml linear gradient from 0% buffer B (50mM Tris-HCl pH 7.5, 400mM NaCl, 10% 
sucrose, 0.1% Triton X-100, 25mM imidazole) to 100% buffer B. Purified protein was 
collected in 1.5ml fractions and stored at -80°C.  
 
Fractions containing protein, as determined by SDS-PAGE and Coomassie blue staining, 
were further purified on a 120ml HiLoad 16/60 Superdex 200pg column (GE, 17-1069-01) 
connected to an ÄKTA Pure FPLC system (GE). A maximum of 5ml sample was applied 
to the column and eluted with 130ml GF buffer (50mM Tris-HCl, 400mM NaCl, 10% 
sucrose). 1.5ml fractions were collected, and protein purity was confirmed by SDS-PAGE 
(10% acrylamide) followed by Coomassie blue staining. Protein identity was confirmed by 
SDS-PAGE followed by western blotting with a primary Penta-His mouse antibody 
(Qiagen, 34660) or HA mouse antibody (Santa Cruz, sc-7392), both at a final concentration 
of 0.2µg/ml, and with a secondary anti-mouse HRP antibody (NEB, 7076). Purified protein 
was stored at -80°C. 
 
WNV replicon 
A WNV replicon (Pierson et al., 2006) was used to study viral replication levels (Figure 
10). Upon transfection of this vector into cells, there is transcription of the replicon by 
RNA polymerase II, followed by translation into proteins (viral non-structural proteins and 
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FLuc). Once the viral proteins are synthesized, they assemble to form the viral genome 
replication complex that produces a large number of copies of the viral RNA that will be 
translated into proteins by the host cell. In order to determine luciferase activity that comes 
from viral replication only, an inactive replicon (mutation D668V in the RNA-dependent 
RNA polymerase active site of the NS5 protein (Gullberg et al., 2015)) is used to measure 
background luciferase activity coming from transcription of the replicon from the plasmid 
by RNA polymerase II and translation of these transcripts. 
 
  
Figure 10. WNV replicon. 
[A] The differences between the virus and the replicon are illustrated. First, the viral 
genome is a (+)ssRNA whereas the replicon is on a DNA plasmid downstream of a CMV 
promoter. Second, the structural proteins are replaced by a firefly luciferase (FLuc) reporter 
gene in the replicon. [B] Map of the replicon plasmid. [C and D] Schematic representation 
of processes taking place when the replicon is transfected into mammalian cells. In the case 
of the wild-type replicon (C), there is transcription of the replicon sequence on the plasmid 
by host cell RNA polymerase II, followed by translation of the transcripts. Once the viral 
non-structural proteins are synthesized, they form the replication complex that produces 
copies of the viral RNA that are then also translated into proteins. In the case of the 
replicon which contains the D668V mutation in the NS5 RdRp active site (D), the 
replication complex is inactive. The only source of luciferase and viral proteins in D668V 
mutants is translation of transcripts that were generated by host cell RNA polymerase II. 
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Site-directed mutagenesis 
Site-directed mutagenesis of the WNV replicon was performed using the QuikChange 
method developed by Agilent. Two custom-made complementary DNA oligonucleotides, 
approximately 35 nucleotides in length, harboring the desired mutation in the center, were 
purchased from Integrated DNA Technologies. A polymerase chain reaction (PCR) was 
performed using 25ng of the wild-type WNV replicon as a template, 0.5µM of each 
oligonucleotide with the desired mutation, 0.5mM dATP (Sigma-Aldrich, D4788), 0.5mM 
dCTP (Sigma-Aldrich, D4913), 0.5mM dGTP (Sigma-Aldrich, D5038), 0.5mM dTTP 
(Sigma-Aldrich, T9656), 5% DMSO, 1.5X PfuUltra Reaction Buffer AD and 2.5U 
PfuUltra High-fidelity DNA Polymerase AD (Agilent, 600385) in a total volume of 25µl. 
After an initial denaturation at 92°C for 2min, 20 three-step cycles (denaturation at 92°C 
for 50sec, annealing at 60°C for 50sec and elongation at 68°C for 34min) as well as a final 
elongation at 68°C for 10min were carried out. The sample was then subjected to a 
restriction digest with 1µl DpnI (NEB, R0176S) to degrade template DNA. 5µl of the 
digested PCR product was then transformed into Escherichia coli XL1 blue cells. 
Transformants were grown on LB plates containing 100µg/ml ampicillin at 37°C over 
night.  
 
A few isolated colonies were picked and grown in 5ml LB medium containing 100µg/ml 
ampicillin at 37°C over night. Plasmid DNA was extracted using a commercially available 
miniprep kit according to the manufacturer’s instructions (Sigma-Aldrich, PLN350). 
Purified plasmid DNA was sequenced to confirm the introduction of the desired mutation 
into the replicon. In order to obtain sufficient amounts of the replicon for downstream 
applications, plasmid DNA was extracted from a 100ml overnight culture using a midiprep 
(Sigma-Aldrich, NA0200) or maxiprep (OMEGA bio-tek, D6922) kit. 
 
Luciferase assay 
BHK17 cells were grown at 37°C and 5% CO2 in DMEM (Wisent, 319-015-CL) 
supplemented with 10% FBS (Wisent, 080-150) and 1mM sodium pyruvate (Wisent, 600-
110-EL). 24h prior to transfection, cells were seeded into 12-well plates at a concentration 
of 50,000 cells per well. They were then transfected with 250ng of the replicon using 0.5µl 
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Lipofectamine 2000 transfection reagent (Invitrogen, 11668019) in opti-MEM (Gibco, 
31958070). The luciferase activity was determined 48h post-transfection by mixing 10µl of 
cell lysate (total amount of lysate for each well: 200µl) with 50µl of luciferase assay 
substrate (Promega, E4550) and measuring emitted light with a GloMax 20/20 
Luminometer (Promega). Data was collected from at least three independent experiments, 
each containing triplicates. Luciferase activity from the wild-type replicon was fixed at 
100%, and luciferase activity from each mutant was expressed relative to the wild-type. A 
one-sample t-test with a hypothetical value of 100 was performed for each mutant. Mutants 
with a p-value below 0.05, 0.005, 0.001 and 0.0001 were labelled with 1 star, 2 stars, 3 
stars and 4 stars, respectively.  
RESULTS 
NS3:NS5 interaction model 
Initial model of the Flavivirus replicase complex 
In order to study the NS3:NS5 interaction as it occurs within the viral replication complex, 
an interaction model including NS3, NS5 and RNA was developed based on data already 
available in the literature, as described above. The model of the replication complex was 
made with proteins from Lineage II WNV because a WNV replicon was available for 
subsequent testing of the model in the lab (Pierson et al., 2006). Known crystal structures 
of the individual full-length proteins as well as location of active sites and RNA binding 
regions were taken into account for the assembly of the three macromolecules into a 
complex. In the resulting model (Figure 11), the NS3:NS5 interaction is mediated by the 
NS3 helicase domain (subdomains 1 and 3) and the NS5 RdRp domain (fingers and thumb 
subdomains). Furthermore, the incoming dsRNA replication intermediate is separated into 
two individual strands by the NS3 helicase, the positive strand being guided into the NS5 
capping enzyme to undergo GTase and MTase reactions for the formation of a complete 
cap structure, and the negative strand being guided through the NS3 helicase domain and 
into the NS5 polymerase domain to serve as template for the synthesis of a new positive 
strand of viral RNA. This way, most of the different enzymatic activities are well 
coordinated for efficient viral replication. Only the NS3 NTPase/RTPase active site is out 
of position for the positive strand to undergo the RTPase reaction before being fed into the 
NS5 capping enzyme domain. However, since this is a preliminary model, the proteins may 
rotate in relation to each other as the model is further developed, and the final position of 
the NTPase/RTPase active site may change. 
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Figure 11. Initial NS3:NS5 interaction model. 
A model for the interaction between NS3, NS5 and RNA within the viral RNA replication 
complex during positive strand synthesis is shown. NS3 and NS5 interact via their helicase 
and RdRp domain, respectively. [A] NS3 is colored in red, NS5 is colored in orange and 
RNA is colored in blue. [B and C] Only the two proteins are shown, and their subdomains 
are differently colored. The NS3:NS5 complex is shown from a side view (B) and from a 
top view (C). In the top view, it is apparent that the RNA binding tunnel of NS3 is in line 
with the template tunnel of NS5. 
 
Hydrogen bonds between the two proteins as well as all residues involved in these 
interactions were identified using PyMOL (Figure 12). Three hydrogen bonds were 
identified: NS3 V276 – NS5 K314, NS3 N278 – NS5 K314 and NS3 K532 – NS5 G750. 
More precisely, the oxygen atom of the NS3 V276 backbone interacts with a hydrogen 
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atom of the amino group on the NS5 K314 side chain, the oxygen atom of the amide group 
on the NS3 N278 side chain interacts with another hydrogen atom of the amino group on 
the NS5 K314 side chain, and a hydrogen atom of the amino group on the NS3 K532 side 
chain interacts with the oxygen atom of the NS5 G750 backbone. In addition, several other 
residues were found to point toward the area between the two proteins, suggesting that they 
might also participate in the interaction: NS3 R218, NS3 R250, NS3 H274, NS3 R275, 
NS3 E529, NS5 S292, NS5 E312 and NS5 E416. 
 
Figure 12. Interactions between NS3 and NS5 in the initial interaction model. 
[A] Three hydrogen bonds between the two proteins were found. [B] Residues involved in 
these interactions. [C] Other residues at the interface between the two proteins that might 
participate in interactions. 
 
Molecular dynamics simulations 
Equilibrated model 
In the interest of improving the NS3:NS5 interaction model, it was submitted to a 
molecular dynamics simulation. The first simulation was very short and it served to 
equilibrate the complex. During this short simulation, the two proteins were found to rotate 
in relation to each other. The interaction surface was increased and eight hydrogen bonds 
between NS3 and NS5 were identified: NS3 R185 – NS5 E416, NS3 K187 – NS5 E416, 
NS3 R216 – NS5 E426, NS3 E306 – NS5 K314, NS3 N503 – NS5 G317, NS3 E523 – NS5 
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R45, NS3 R5225 – NS5 E46 and NS3 R527 – NS5 E46. Of the residues involved in these 
interactions, only one was involved in interactions in the initial model (Figure 13). 
 
Figure 13. Equilibrated NS3:NS5 interaction model. 
[A] Eight hydrogen bonds between the two proteins were found. [B] Residues involved in 
these interactions. 
 
Progression of NS3:NS5 interactions through a 220ns molecular dynamics simulation 
The equilibrated model was subjected to further molecular dynamics simulations. So far, 
the simulation has been carried out for approximately 220ns, and the evolution of the 
complex has been monitored at various time points (Figure 14). Its global structure 
remained almost unchanged compared to the equilibration simulation. The two proteins 
rotated approximately 20° in relation to each other during the first 100ns and then remained 
mostly static, and only small movements were observed. The interactions between NS3 and 
NS5 were sampled at 15ns, 25ns, 100ns, 140ns, 160ns and 220ns during the simulation 
(Figure 15). The number of hydrogen bonds between the two proteins varied between five 
and ten, and residues involved in these interactions also varied during the simulation. Even 
though the interacting pairs fluctuated, many residues involved in interactions at one instant 
were still involved in interactions in later time points, only with a different interacting 
partner (e.g. NS5 K314). Some interactions appeared, stayed stable for some time and then 
disappeared (e.g. NS3 K186 – NS5 E289). Other interactions were maintained during 
almost the entire simulation (e.g. NS3 R216 – NS5 D430). 
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Figure 14. Evolution of the interaction model during MD simulation. 
The global structure of the NS3:NS5 complex at different time points during the molecular 
dynamics simulation is displayed. 
 
 
Figure 15. Interactions between NS3 and NS5 at various time points in the MD 
simulation. 
Interacting residues within the NS3:NS5 complex at different time points during the 
molecular dynamics simulation are listed. Interactions that are maintained between 
different times are connected with lines. 
 
In general, the longer an interaction is stable during a molecular dynamics simulation, the 
higher the chances that this interaction actually takes place in vivo. Therefore, the NS3:NS5 
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interaction model seems to be a quite good model of the real interaction between NS3 and 
NS5. It is expected that the residues that mediate the interaction vary slightly over time 
considering that all interactions are dynamic. 
 
 
 
Figure 16. Interaction model after 220ns MD simulation. 
[A] Side view. [B] Top view. During the MD simulation, the NS3 and NS5 rotated in 
relation to each other (note that the MD simulation did not include RNA which would 
restrict the degrees of freedom of the complex). The helical gate, the NS3 RNA binding 
tunnel and the NS5 RNA template channel are still aligned. However, the NS3 RTPase 
active site is no longer near the NS5 capping enzyme domain.  
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The overall evolution of the NS3:NS5 complex is quite interesting. As shown in Figure 16, 
the RNA-binding tunnel of the NS3 helicase domain and the RNA template channel of the 
NS5 RdRp domain are still aligned, allowing the negative strand RNA to be fed into the 
polymerase after dsRNA unwinding at the helical gate. However, the two proteins rotated 
in relation to each other, and the ATPase/RTPase active site moved even further away from 
the capping enzyme domain. Therefore, the positive strand RNA would be able to undergo 
the first step of the capping reaction at the RTPase site, but it would not be near the capping 
enzyme domain for the two other reactions. Nevertheless, the model presented here may be 
valid. The NS5 protein has been shown to be flexible, and various conformations and 
relative orientations of the two domains have been reported (Bussetta and Choi, 2012; Lu 
and Gong, 2013; Zhao et al., 2015b). It is possible that the crystal structure of NS5 used for 
the development of the NS3:NS5 interaction model is not in the right conformation for 
positive strand synthesis, and that the MTase domain is actually positioned in a way that 
would allow the coupling of the RTPase, GTase and MTase reactions. Alternatively, the 
replicase complex may have a stoichiometry other than 1:1, and the positive strand RNA 
may be fed into the capping enzyme domain of a different NS5 protein within the complex. 
 
Production of recombinant proteins for protein interaction analysis 
In order to test the NS3:NS5 model developed in silico, an in vitro interaction assay which 
uses purified proteins is currently being developed. Both NS3 and NS5 have been cloned 
into expression vectors for the production of recombinant proteins in E. coli. Point 
mutations of the amino acid residues that mediate the NS3:NS5 interaction per the 
interaction model presented here were introduced into the NS3 and NS5 coding sequences. 
Once expressed and purified, these proteins (wild-type and mutants) can be used to 
measure the interaction between NS3 and NS5 in the presence and absence of RNA in 
vitro. Moreover, the effects of the mutations on the enzymatic activities of NS3 and NS5 
can be assessed to further characterize the role of the mutated residues.  
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Protein expression 
Expression of recombinant NS2B49-66-NS3-HA-6His and NS5-6His was tested in three 
different strains of Escherichia coli (Figure 17). Expression of NS2B49-66-NS3 was found to 
be optimal in BL21(DE3) cells whereas expression of NS5 was maximal in 
Rosetta2(DE3)pLysS cells. 
 
Figure 17. Expression of recombinant proteins in different E. coli strains. 
Expression of both NS2B49-66-NS3 and NS5 was tested in BL21(DE3) cells, 
HMS174(DE3) cells and Rosetta2(DE3)pLysS cells. [A] Bacterial lysates before and after 
the induction of NS2B49-66-NS3 expression. [B] Bacterial lysates before and after the 
induction of NS5 expression. [C] Bacterial lysates after the induction of NS2B49-66-NS3 and 
NS5 expression.  
 
 
 
Figure 18. Purification of recombinant proteins. 
Purified proteins were analyzed by SDS-PAGE. [A] Protein purity was confirmed by 
Coomassie blue staining. [B] Both NS2B49-66-NS3-HA-6His and NS5-6His were revealed 
on an anti-6His western blot. [C] Only NS2B49-66-NS3-HA-6His was revealed on an anti-
HA western blot.  
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Protein purification 
Given that both NS2B49-66-NS3 and NS5 are fused in-frame with a 6His tag, both proteins 
were purified by affinity chromatography on a HisTrap HP column. Full-length proteins 
were co-purified with the individual domain that contained the 6His-tag (data not shown). 
Therefore, eluates were further purified by size exclusion. Full-length proteins were 
successfully separated from the individual domains (Figure 18). 
 
To date, out of 54 mutants to be made, 47 have been confirmed by sequencing, 43 have 
been expressed, 24 have been purified by affinity chromatography and 16 have been 
purified by gel filtration chromatography (Appendix 5). As the project moves forward, they 
will be tested in biochemical assays. These experiments will help characterize the NS3:NS5 
interaction in the presence and absence of RNA in vitro and prove or disprove the 
interaction model presented here (see discussion). 
 
Assessment of potential interacting residues on viral replication efficiency 
A WNV replicon (Pierson et al., 2006) was used for further testing of the interaction model 
and characterization of the NS3:NS5 interaction in a more complex cellular environment. 
Point mutations of residues involved in the NS3:NS5 interaction were introduced into the 
WNV replicon, and the effect of these mutations on viral replication was determined. 
 
 
Figure 19. WNV replicon time course. 
The wild-type WNV replicon as well as the inactive NS5 D668V mutant were transfected 
into cells, and luciferase activity was measured at 1h, 2h, 4h, 8h, 16h, 24h, 48h and 72h 
post-transfection. Results are shown on a linear scale [A] and on a logarithmic scale [B]. 
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A time course experiment with the WNV replicon was conducted to determine how long it 
takes for the replicon plasmid to be transcribed and translated into viral proteins that form 
an active replication complex (Figure 19). As soon as 4h post-transfection, luciferase 
activity began to increase, indicating that the replicon plasmid had entered cells and was 
being transcribed, and the resulting transcripts were translated into proteins. Up to 24h 
post-transfection, the luciferase activity from the wild-type replicon as well as from the 
inactive NS5 D668V mutant were the same, suggesting that there was only transcription of 
the replicon from the plasmid by RNA polymerase II and translation of these transcripts but 
no activity of the viral replication complex. At 48h and 72h post-transfection, there was a 
47.8-fold and a 210.7-fold difference in the luciferase activity of cells transfected with the 
wild-type replicon and the NS5 D668V mutant, respectively. These results indicate that 
most of the luciferase activity measured after 48h is attributable to viral replication. 
Therefore, all subsequent luciferase assays were performed at 48h post-transfection. 
 
Mutants from the initial model 
Residues potentially involved in the NS3:NS5 interaction according to the initial interaction 
model (Figure 12) were mutated on the WNV replicon, and the effect of these mutations on 
viral replication was determined (Figure 20, Appendix 6). More precisely, the residues 
involved in hydrogen bonds between NS3 and NS5 were substituted by alanine (Figure 
19a) as well as by similar residues (Figure 20b). Potential compensatory mutations were 
also made (Figure 20c). Finally, several other residues at the interface between the two 
proteins were substituted by alanine (Figure 20d). 
 
Mutants could be divided into three groups: some had little to no effect on viral replication, 
some had a moderate effect and some severely affected replication. Substitution of NS3 
V276 with alanine and leucine reduced replication to 5.7% and 62.9%, respectively. 
Interestingly, modifications on the side chain of NS3 V276 affects the level of viral 
replication, although the interaction with NS5 would be mediated by its backbone 
according to our model. Substitution of NS3 N278 with alanine, aspartate and glutamine 
yielded replication levels of 41.3%, 4.4% and 52.0%, respectively. These results indicate 
that the amide group on the side chain is important, possibly for the interaction with NS5 as  
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Figure 20. Viral replication levels of mutants based on the initial interaction model.  
[A] Alanine substitutions of the residues involved in interactions. [B] Conservative 
mutations of the residues involved in interactions. [C] Compensatory mutations. [D] 
Alanine substitutions of other residues possibly involved in interactions. 
 
suggested by the interaction model. In addition, the length of the side chain seems to play 
an important role, since it is the only difference between asparagine and glutamine, but 
substitution of the asparagine by glutamine reduces replication to 52.0%. The double 
mutant NS3 V276A-N278A severely affects viral replication with a residual level of 1.5%. 
Most of the effect can be attributed to the substitution of V276, although the substitution of 
N278 seems to contribute given that replication of the V276A mutant alone was slightly 
higher with 5.7%. Substitution of NS3 K532 to alanine and arginine produced replication 
levels of 41.9% and 101.3%, respectively, suggesting that a basic group at this position is 
of importance. Very similar results were observed for the mutation of NS5 K314 to alanine 
and arginine, yielding replication levels of 55.2% and 102.0%, respectively. Substitution of 
NS5 G750 with alanine and proline resulted in 87.7% and 3.5% replication, respectively. 
These results indicate that this glycine does not interact with the NS3 protein. The drastic 
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reduction of replication in the G750P mutant is most likely due to a change in the local 
structure that displaces other residues involved in the NS3:NS5 interaction. The double 
mutant NS5 K314A-G750A reduced replication to 64.9% which is close to the residual 
replication of the K314A mutation alone, confirming that G750 does not participate in the 
interaction with NS3. In order to further investigate if the identified residues really interact 
with each other, compensatory mutants were made. If two residues interact, then mutating 
one of them would disrupt the interaction, but mutating both of them would re-establish the 
interaction and thus viral replication. None of the three double mutants yielded a higher 
replication level than the corresponding individual mutants, suggesting that those particular 
residues do not interact directly. Finally, among the other residues at the interface between 
the two proteins, NS3 R218 and NS3 R250 were found to be critical since their substitution 
by alanine caused replication to drop to 2.7% and 10.7%, respectively. Substitution of NS3 
H274, NS3 E529 and NS5 S292 had a moderate effect on viral replication, and mutation of 
NS3 R250, NS5 E312 and NS5 E416 did not significantly affect replication. Overall, some 
residues involved in interactions according to the model were shown to be crucial for 
efficient viral replication whereas others seemed to be of little importance. These results 
were expected, since all mutants were based on a preliminary interaction model developed 
by manual docking, and it was unlikely that all residues that are critical for the NS3:NS5 
interaction would have been identified right away. Nevertheless, this model was a very 
good starting point for the detailed characterization of the interaction between NS3 and 
NS5. 
 
Mutants from models during the molecular dynamics simulations 
Mutants from the equilibrated model 
All the residues involved in hydrogen bonds per the equilibrated model were mutated in the 
WNV replicon, and viral replication was measured for each mutant (Figure 21, Appendix 
6). 
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Figure 21. Viral replication levels of mutants based on the equilibrated interaction 
model. 
Residues involved in hydrogen bonds according to the equilibrated interaction model were 
substituted by alanine in the WNV replicon and the effects of those mutations on viral 
replication were measured. 
 
Alanine substitutions of residues R216, E523, R525 and R527 on NS3 were found to 
drastically reduce viral replication to 0.2%, 1.2%, 2.3% and 0.8%, respectively. In addition, 
substitution of NS3 R185 and NS3 N503 moderately reduced replication to 64.8% and 
41.3%, respectively. Mutations of NS3 K187 and NS3 E306 had no significant effect on 
replication. Only one alanine substitution on NS5 had a severe effect on replication: the 
G317A mutant yielded 0.3% replication. Substitution of NS5 K314 reduced replication to 
55.2%, substitution of NS5 R45, E416 and E426 did not significantly affect replication, and 
substitution of NS5 E46 by alanine even increased replication to 139.3%. The identification 
of four additional residues on NS3 that abolish viral replication suggests that this region on 
NS3 is indeed crucial for replication, presumably because of its interaction with NS5. 
However, given that only one mutation on NS5 greatly reduced replication, the model 
needs to be further improved to identify the region on NS5 that interacts with NS3. 
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Mutants from models at different times during the 220ns molecular dynamics simulation 
All residues involved in hydrogen bonds at some time during the molecular dynamics 
simulation were mutated in the replicon and viral replication was measured for each mutant 
(Figure 22, Appendix 6). As before, the mutants can be divided into three groups. Some 
have little to no effect on viral replication, some have a moderate effect and some severely 
impair replication. Interestingly, there are more NS3 mutants than NS5 mutants that are 
deleterious for replication. Furthermore, among the mutants that allow replication, 
mutations on NS3 generally have a greater negative effect on replication than mutations on 
NS5 (Figure 23, Appendix 6). These finding suggest that the surface region on NS3 in 
which the mutated residues are clustered is important for viral replication, presumably 
because it mediates the interaction with NS5. However, the corresponding region on NS5 
has not been entirely determined, and further MD simulations are necessary. 
 
Figure 22. Viral replication levels of mutants based on models at various time points 
in the MD simulation. 
Residues involved in hydrogen bonds at 15ns, 25ns, 100ns, 140ns, 160ns and/or 220ns into 
the MD simulation were substituted by alanine in the WNV replicon and the effects of 
those mutations on viral replication were measured. 
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Figure 23. Interacting residues at different time points during the MD simulation and 
the importance of those residues for viral replication. 
Interacting residues within the NS3:NS5 complex at different time points during the 
molecular dynamics simulation are shown. Residues are colored according to viral 
replication levels when they substituted by alanine. Residues that show <5% replication are 
red, 5-20% are orange, 20-50% are yellow and >50% are green. 
 
 
 
 
DISCUSSION 
A preliminary interaction model of the WNV replicase complex which includes NS3, NS5 
and viral RNA has been developed. Data already available in the literature, such as crystal 
structures of the individual proteins, locations of catalytic active sites and known RNA-
binding regions were taken into account, and the three macromolecules were assembled in a 
way that would allow coupling of the respective enzymatic activities of NS3 and NS5 and 
thus favour efficient viral replication. The resulting NS3:NS5 complex without RNA was 
submitted to a molecular dynamics simulation of approximately 220ns, and its evolution 
was monitored at various time points during the simulation. For all versions of the 
NS3:NS5 interaction model (initial model and models during the MD simulation), the 
amino acid residues that mediate the interaction between NS3 and NS5 were determined. 
These residues were substituted by alanine in a WNV replicon, and the effects of these 
mutations on viral replication were evaluated. In general, mutants could be divided into 
three groups: some had little effect on replication, some had a moderate effect, and some 
severely impaired replication. More precisely, alanine substitution of K186, R216, R218, 
G254, E523, R525 and R527 on NS3 as well as N48 and G317 on NS5 reduced viral 
replication to less than 5% of the wild-type replicon.  
 
Figure 24. Mutations that severely affect viral replication. 
Residues whose substitution by alanine reduces viral replication to less than 5% of the 
wild-type replicon were mapped onto the NS3:NS5 interaction model after 220ns of MD 
simulation and displayed as green sticks. 
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Residues K186, R216, R218 and G254 are located on the NS3 helicase subdomain 1 
whereas E523, R525 and R527 are located on subdomain 3. Regarding the two residues on 
NS5, N48 is part of the capping enzyme domain and G317 is located on the RdRp fingers 
subdomain (Figure 24). These findings are slightly different from results obtained by other 
groups who have suggested that the NS3:NS5 interaction is mediated by the NS3 helicase 
domain and the NS5 RdRp domain, with residues 566-585 of the helicase subdomain III 
and residues 320-341 of the RdRp thumb subdomain being essential for the interaction 
(Tay et al., 2015; Zou et al., 2011). However, when these two regions are placed in close 
proximity and the RNA-binding grooves of the NS3 helicase domain and the NS5 RdRp 
domain are aligned, the resulting NS3:NS5 complex does not appear functional (Figure 25).  
 
Figure 25. Comparison of our NS3:NS5 interaction model with findings of other 
groups.  
[A] Residues NS3 566-585 and NS5 320-341 were mapped onto the NS3:NS5 interaction 
model after 220ns of MD simulation and colored in green. The NS3 helicase domain is 
colored in orange, the NS5 capping enzyme domain in teal, and the NS5 RdRp domain in 
red. [B] NS3 and NS5 were rotated in relation to each other to allow interaction of the 
above-mentioned regions, and the RNA-binding tunnels of the NS3 helicase domain and 
the NS5 RdRp domain were aligned.  
 
The helical gate, where the dsRNA is split into two individual strands, is located close to 
the interface between NS3 and NS5, and there does not seem to be enough space to 
accommodate a dsRNA at this site. Moreover, the RNA-binding tunnels of the two proteins 
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are aligned, but the RNA would flow through the NS3 helicase and the NS5 RdRp in 
opposite directions, which seems very unlikely. Therefore, residues 566-585 of NS3 and 
residues 320-341 of NS5 may mediate the interaction between the two proteins in vitro or it 
may be an experimental artifact due to the biased SAXS data, but this interaction is very 
improbable to occur within the replicase complex during positive strand synthesis in vivo. 
Our NS3:NS5 interaction model proposes an alternative means of interaction between these 
two proteins. In addition, as opposed to interaction models proposed by other groups, it 
takes into account how the proteins would actually work together at the molecular level 
during positive strand RNA synthesis, and it considers viral RNA as a replicase complex 
component.  
 
Here I report the results from two different approaches used to test the preliminary 
NS3:NS5 interaction model, namely an in silico MD simulation and an in vitro replication 
assay (summarized in Figure 23). The MD simulation shows that the NS3:NS5 complex is 
relatively stable over time with four interactions (NS3 K186 – NS5 E416, NS3 R216 – NS5 
Q420, NS3 R216 – NS5 D430, NS3 R527 – NS5 E46) being maintained during almost the 
entire simulation. This suggests that the seven residues involved in these four interactions 
are indeed important for the interaction between NS3 and NS5. However, when these 
residues are substituted in the WNV replicon and viral replication is determined for each 
mutant, only some mutations significantly reduce viral replication. More precisely, NS3 
K186A, NS3 R216A, and NS3 R527A show less than 5% of replication compared to the 
wild-type, NS5 D430A shows approximately 16% of replication compared to the wild-type 
whereas NS5 E46A, NS5 E416A and NS5 Q420A show more than 50% of replication 
compared to the wild-type replicon. These results confirm that NS3 K186, NS3 R216, NS3 
R527, and to a lesser extent NS5 D430 are important for viral replication, presumably 
because they contribute to the NS3:NS5 interaction. However, the results from the 
replication assay also suggest that NS5 E46, NS5 E416 and NS5 Q420 do not play an 
important role in viral replication, and might therefore not be crucial for the interaction 
between NS3 and NS5, which is inconsistent with the results from the MD simulation. This 
discrepancy highlights the need for further validation of the NS3:NS5 interaction model 
with at least one other method. Moreover, there is the possibility that the low replication 
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levels observed in the cell-based assay are due to another reason than the loss of the 
NS3:NS5 interaction, for example less expression of the viral proteins from the mutant 
replicons than from the wild-type replicon, or misfolding of the mutant proteins which 
leads to impaired catalytic activity. Therefore, validation of the preliminary results 
presented here is necessary to discard these possibilities and clearly link the loss of viral 
replication to the loss of NS3:NS5 interaction. For example, lysates from cells transfected 
with the replicons could be analyzed by western blotting to confirm that the protein 
expression levels from all mutant replicons is the same as from the wild-type replicon. This 
would require specific antibodies against the viral proteins, which are currently not 
commercially available, or fusing the viral proteins to tags that can be detected with 
specific antibodies. However, introducing tags into the replicon is likely to interfere with 
polyprotein processing and/or protein activity. Alternatively, recombinant NS3 and NS5 
could be expressed in E. coli and purified to verify proper folding of all mutants using 
circular dichroism spectroscopy, and to test enzymatic activities using various in vitro 
assays. Theoretically, results from these experiments should be the same for wild-type and 
mutant proteins. Finally, an in vitro interaction assay would allow to directly measure the 
interaction between recombinant NS3 and NS5 (wild-type or mutant) and thus determine if 
there is a correlation between the loss of viral replication and the loss of protein-protein 
interaction. This would prove the importance of the NS3:NS5 interaction for replication 
and would provide evidence that this protein-protein interaction may be an interesting 
target for the development of antiviral compounds. Furthermore, it could be interesting to 
combine multiple mutations that greatly reduce the NS3:NS5 interaction and thus viral 
replication, for example NS3 K186A, NS3 R216A and NS3 R527A, and investigate if such 
a mutant virus could be a vaccine candidate. However, this would require an animal model 
as well as the infectious virus instead of the replicon, and since WNV is a biosafety level 3 
pathogen, these experiments might be a bit more difficult to realize. 
 
Future work 
As mentioned earlier, further MD simulations are required to determine the surface region 
on NS5 that interacts with NS3, and RNA should be added to the two proteins for a better 
model of the replicase complex. Moreover, biochemical interaction data is needed to 
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confirm that loss in viral replication observed upon mutations in the WNV replicon is 
indeed due to loss of NS3:NS5 interaction.  
 
In vitro NS3:NS5 interaction assay 
Recombinant NS3 and NS5 proteins (wild-type and mutants) have been expressed in E. coli 
and purified by affinity and size exclusion chromatography. They will be used in a Biacore 
surface plasmon resonance (SPR) assay. These experiments will determine the binding 
affinity of the two proteins for each other (Kd) as well as the stoichiometry of the NS3:NS5 
complex. Results from these assays will help prove or disprove the model presented here 
regarding the number of NS3 and NS5 proteins in the replicase complex. Moreover, by 
comparing the interaction between the two wild-type proteins and one mutant protein with 
the other wild-type protein, the results from these experiments will contribute to the 
determination of key residues for the NS3:NS5 interaction. In preparation for the SPR 
assay, the optimal pH for the amine coupling of an HA antibody to a CM5 chip has been 
determined (Figure 26).  
 
Figure 26. pH scouting for the amine coupling of the HA antibody to the CM5 chip. 
The optimal pH for the covalent binding of the HA antibody to the CM5 chip was 
determined to be 4.0.  
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Once the HA antibody is covalently bound to the chip, purified HA-tagged NS3 will be 
injected and retained on the chip due to its affinity for the HA antibody. Then, purified NS5 
will be injected and its binding to NS3 will be measured. Finally, both NS3 and NS5 will 
be washed off of the chip, and it will be ready for the next assay. Using this method, the 
affinity of all NS3 mutants for wild-type NS5 as well as the affinity of all NS5 mutants for 
wild-type NS3 will be determined. In addition, the Kd of the NS3:NS5 interaction in the 
presence and absence of RNA will be measured. If there is a correlation between the 
NS3:NS5 interaction in vitro and viral replication in cells, it will be reasonable to conclude 
that the NS3:NS5 interaction is essential for an efficient viral replication, and this 
interaction could be a new target for the development of antiviral drugs. 
 
Flavivirus drug development 
Despite several decades of research efforts, no specific antiviral drugs are currently 
available to treat and cure Flavivirus infections. Therefore, new antiviral strategies, 
including new drug candidates and/or new targets, are greatly needed. Understanding how 
Flaviviruses work on a molecular level, for example during positive strand RNA synthesis, 
will help in uncovering new points for therapeutic intervention. 
 
NS3 and NS5 as drug targets 
Given that both NS3 and NS5 have been well characterized, they have been studied as 
targets for antiviral drug development. Several compounds that inhibit one of the enzymatic 
activities of NS3 in vitro have been identified, yet none has been approved for clinical trials 
due to the lack of specific binding pockets for helicase inhibitors which likely leads to 
significant toxicity (Luo et al., 2015), or because of low specificity, permeability and 
stability in the case of protease inhibitors (Brecher et al., 2013; Lim et al., 2013b). As for 
NS5, few MTase inhibitors have been identified, most of which are not cell permeable and 
thus have not been further developed (Lim et al., 2015). Regarding the NS5 RdRp, many 
inhibitory compounds have been found, most of which did not reach the preclinical stage 
(Lim et al., 2015). Of the compounds that have been retained as drug candidates, one was 
associated with toxicity in preclinical trials (Yin et al., 2009), and one showed no efficacy 
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in a phase II clinical trial (Nguyen et al., 2013). One NS5 inhibitor is currently in a phase 
II/III clinical trial in Thailand (Lim et al., 2015; NIH, 2017). 
 
So far, most studies aiming to identify antiviral drug candidates have focussed on searching 
inhibitors that target an active site of one of the domains of NS3 or NS5. However, 
compounds found using this approach may work well in vitro, but there is a considerable 
risk of non-specificity which is associated with toxic effects. In fact, the catalytic sites of 
viral enzymes resemble the catalytic sites of host cell enzymes that execute the same or a 
similar function, and it is challenging to develop inhibitors that target the viral enzyme 
without affecting the host cell enzyme (Lim et al., 2013b). One way to avoid these toxicity 
issues is to choose a target that is very specific to the virus, like the interaction between two 
viral proteins. 
 
Protein-protein interactions as drug targets 
Any interaction between viral proteins that is crucial for viral replication could be a 
potential drug target. So far, the NS2B:NS3 (Brecher et al., 2013; Chappell et al., 2008), 
NS3:NS4B (Zou et al., 2015a), NS4A:NS4B (Zou et al., 2015b) and NS3:NS5 (Takahashi 
et al., 2012; Zou et al., 2011) interactions have been proposed to be interesting targets for 
antiviral therapeutics. Since interactions between viral proteins most likely do not resemble 
any interaction between cellular proteins, they are potentially very specific targets, and 
inhibitors might be less likely to cause toxicity. In addition, given that the inhibitory 
compound does not need to mimic an endogenous molecule, there are many possible 
chemotypes that can bind efficiently (Mullard, 2012). In order to target a protein-protein 
interaction (PPI), this interaction needs to be structurally well characterized and key 
residues or binding regions on the proteins should be identified (Arkin and Wells, 2004). 
The detailed characterisation of the NS3:NS5 interaction presented here provides the basis 
for the search of compounds that might interfere with this protein-protein interaction and 
that might be interesting candidates for the development of specific drugs against 
Flaviviruses. 
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At this stage, two surface regions of NS3, involving residues K186/R216/R218/G254 and 
E523/R525/R527, as well as two residues on NS5, N48 and G317, have been shown to be 
critical for viral replication and could therefore be attractive targets for the development of 
inhibitory compounds of the NS3:NS5 interaction. Given that a single point mutation of 
any of these residues reduces viral replication to less than 5% of the wild-type, targeting 
only one of these four regions with an inhibitor will most likely be sufficient to disrupt the 
interaction between NS3 and NS5. In fact, it has been shown that only a small proportion of 
residues at protein-protein interfaces, which are clustered in so-called “hot spots”, are 
critical for the interaction and confer most of the binding energy, and that PPI inhibitors 
bind these hot spots and not the entire protein-protein interface (Arkin et al., 2014). 
Regarding the nature of inhibitors, both small molecules and peptides have been shown to 
successfully interfere with PPIs (Arkin et al., 2014; Arkin and Wells, 2004). Therefore, 
once the NS3:NS5 interaction model is final, it can be used for in silico drug screening 
using Autodock or Autodock Vina and different drug libraries, and PPI hot spots on both 
NS3 and NS5 can be targeted. Compounds that have a good binding affinity can then be 
purchased and tested for their antiviral potential. At first, they could be used in an in vitro 
interaction assay to determine if they are able to interfere with the NS3:NS5 interaction. 
Next, cells transfected with the wild-type replicon could be treated with the potential 
inhibitors to assess their ability to restrict viral replication. Finally, it would be interesting 
to test their antiviral potential as well as their toxicity in the context of an actual infection, 
in cells and/or in an animal model.  
 
Importance of the project & my contributions 
I contributed to the project presented here in multiple ways. I visually analyzed the 
different stages of the NS3:NS5 interaction model developed in silico to determine the 
amino acid residues on both proteins that mediate the NS3:NS5 interaction. I also 
participated in the design of the wet lab experiments, and I carried out the in vitro and cell 
culture work. Finally, I generated the figures presented here and I wrote this thesis. 
 
This project has moved the field forward by proposing the first model of the Flavivirus 
replicase complex that includes viral RNA as a major component of the complex and that 
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addresses how the NS3 and NS5 proteins would work together at the molecular level. 
Methods to test this model even in the absence of a co-crystal structure have been shown. 
Understanding how NS3 and NS5 interact within the replicase complex will help define the 
mechanism of positive strand synthesis and potentially uncover new points for therapeutic 
intervention. 
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Appendix 1. Alignment of the NS3 proteins from DENV, YFV, WNV, JEV and ZIKV. 
Sequences were aligned using PRALINE (Centre for Integrative Bioinformatics Vrije 
Universiteit Amsterdam, 2017). Each amino acid residue is colored according to its 
conservation between these virus species, where red is most conserved and blue is least 
conserved. 
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PDB code Virus Protein Ligands Resolution Authors 
2FOM DENV NS3 protease  - 1.5Å (Erbel et al., 2006) 
2FP7 WNV NS3 protease Substrate-based inhibitor 1.68Å (Erbel et al., 2006) 
2GGV WNV NS3 protease  - 1.8Å (Aleshin et al., 2007) 
2IJO WNV NS3 protease Pancreatic trypsin inhibitor 2.3Å (Aleshin et al., 2007) 
2M9P DENV NS3 protease Peptide-like inhibitor NMR (Gibbs et al., to be published) 
2M9Q DENV NS3 protease Peptide-like inhibitor NMR (Gibbs et al., to be published) 
2YOL WNV NS3 protease Substrate analog inhibitor 3.2Å (Hammamy et al., 2013) 
3E90 WNV NS3 protease Substrate-based inhibitor 2.45Å (Robin et al., 2009) 
3L6P DENV NS3 protease  - 2.2Å (Chandramouli et al., 2010) 
3LKW DENV NS3 protease  - 2.0Å (Chandramouli et al., 2010) 
3U1I DENV NS3 protease Peptide-based inhibitor 2.3Å (Noble et al., 2012) 
3U1J DENV NS3 protease Pancreatic trypsin inhibitor 1.8Å (Noble et al., 2012) 
4M9F DENV NS3 protease  - 2.7Å (Yildiz et al., 2013) 
4M9I DENV NS3 protease  - 2.4Å (Yildiz et al., 2013) 
4M9K DENV NS3 protease  - 1.46Å (Yildiz et al., 2013) 
4M9M DENV NS3 protease  - 1.53Å (Yildiz et al., 2013) 
4M9T DENV NS3 protease  - 1.74Å (Yildiz et al., 2013) 
4R8T JEV NS3 protease  - 2.13Å (Weinert et al., 2015) 
5GJ4 ZIKV NS3 protease  - 1.84Å (Phoo et al., 2016)  
5GPI ZIKV NS3 protease  - 1.58Å (Z. Zhang et al., 2016) 
5H4I ZIKV NS3 protease Compound fragment 2.0Å (Z. Zhang et al., 2016) 
5IDK WNV NS3 protease Dipeptide boronic acid inhibitor 1.5Å (Nitsche et al., 2016) 
5LC0 ZIKV NS3 protease Dipeptide boronic acid inhibitor 2.7Å (Lei et al., 2016) 
5T1V ZIKV NS3 protease  - 3.1Å (Nocadello et al., to be published) 
1YKS YFV NS3 helicase  - 1.8Å (Wu et al., 2005) 
2BHR DENV NS3 helicase  - 2.8Å (Xu et al., 2005) 
2BMF DENV NS3 helicase  - 2.41Å (Xu et al., 2005) 
2JLQ DENV NS3 helicase  - 1.67Å (Luo et al., 2008b) 
2JLR DENV NS3 helicase AMP-PNP 2.0Å (Luo et al., 2008b) 
2JLS DENV NS3 helicase ADP 2.23Å (Luo et al., 2008b) 
2JLU DENV NS3 helicase ssRNA 2.04Å (Luo et al., 2008b) 
2JLV DENV NS3 helicase AMP-PNP, ssRNA 1.9Å (Luo et al., 2008b) 
2JLW DENV NS3 helicase ssRNA 2.6Å (Luo et al., 2008b) 
2JLX DENV NS3 helicase ADP-vanadate, ssRNA 2.2Å (Luo et al., 2008b) 
2JLY DENV NS3 helicase ADP, ssRNA 2.4Å (Luo et al., 2008b) 
2JLZ DENV NS3 helicase ADP, ssRNA 2.2Å (Luo et al., 2008b) 
2QEQ KUNV NS3 helicase  - 3.1Å (Mastrangelo et al., 2007) 
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2Z83 JEV NS3 helicase  - 1.8Å (Yamashita et al., 2008) 
5FFM YFV NS3 helicase  - 2.6Å (Wu et al., 2005) 
5GJC ZIKV NS3 helicase ATP 2.2Å (Tian et al., 2016b) 
5JMT ZIKV NS3 helicase  - 1.8Å (Tian et al., 2016a) 
5JRZ ZIKV NS3 helicase PPi 1.62Å (Jain et al., 2016) 
5JWH ZIKV NS3 helicase  - 1.4Å (Cao et al., 2016) 
5K8I ZIKV NS3 helicase ATP 1.69Å (Cao et al., 2016) 
5K8L ZIKV NS3 helicase GTPγS 1.75Å (Cao et al., 2016) 
5K8T ZIKV NS3 helicase GTPγS 1.85Å (Cao et al., 2016) 
5K8U ZIKV NS3 helicase ADP 1.6Å (Cao et al., 2016) 
5MFX ZIKV NS3 helicase ssRNA 1.6Å (Jenkins et al., to be published) 
5TXG ZIKV NS3 helicase  - 2.05Å (Nocadello et al., to be published) 
2VBC DENV NS3 full-length  - 3.15Å (Luo et al., 2008a) 
2WHX DENV NS3 full-length ADP 2.2Å (Luo et al., 2010) 
2WZQ DENV NS3 full-length  - 2.8Å (Luo et al., 2010) 
 
Appendix 2. Structures of NS3 protease, NS3 helicase or full-length NS3 of DENV, 
YFV, WNV, JEV and ZIKV. 
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Appendix 3. Alignment of the NS5 proteins from DENV, YFV, WNV, JEV and ZIKV. 
Sequences were aligned using PRALINE (Centre for Integrative Bioinformatics Vrije 
Universiteit Amsterdam, 2017). Each amino acid residue is colored according to its 
conservation between these virus species, where red is most conserved and blue is least 
conserved. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  79
PDB code Virus Protein Ligands Resolution Authors 
1L9K DENV NS5 capping enzyme SAH 2.4Å (Egloff et al., 2002) 
1R6A DENV NS5 capping enzyme SAH, ribavirin 2.6Å (Benarroch et al., 2004a) 
2OY0 WNV NS5 capping enzyme SAH 2.8Å (Zhou et al., 2007) 
2P1D DENV NS5 capping enzyme SAH, GMP 2.9Å (Egloff et al., 2002) 
2P3L DENV NS5 capping enzyme SAH, GpppA 2.2Å (Egloff et al., 2007) 
2P3O DENV NS5 capping enzyme SAH, m7GpppA 2.76Å (Egloff et al., 2007) 
2P3Q DENV NS5 capping enzyme SAH, GpppG 2.75Å (Egloff et al., 2007) 
2P40 DENV NS5 capping enzyme m7GpppG 2.7Å (Egloff et al., 2007) 
2P41 DENV NS5 capping enzyme SAH, m7GpppGm 1.8Å (Egloff et al., 2007) 
2XBM DENV NS5 capping enzyme SAH, GpppA-GAACCUGA 2.9Å (Yap et al., 2010) 
3EVA YFV NS5 capping enzyme SAH 1.5Å (Geiss et al., 2009) 
3EVB YFV NS5 capping enzyme SAH 1.85Å (Geiss et al., 2009) 
3EVC YFV NS5 capping enzyme SAH, GTP 1.6Å (Geiss et al., 2009) 
3EVD YFV NS5 capping enzyme SAH, GTP 1.5Å (Geiss et al., 2009) 
3EVE YFV NS5 capping enzyme SAH, GpppA 1.7Å (Geiss et al., 2009) 
3EVF YFV NS5 capping enzyme SAH, m7GpppA 1.45Å (Geiss et al., 2009) 
3EVG DENV NS5 capping enzyme SAH 2.2Å (Geiss et al., 2009) 
3LKZ WNV NS5 capping enzyme Sinefungin 2.0Å (Dong et al., 2010) 
3P8Z DENV NS5 capping enzyme SAH / inhibitor 1.7Å (Lim et al., 2011) 
3P97 DENV NS5 capping enzyme SAM 1.7Å (Lim et al., 2011) 
4CTJ DENV NS5 capping enzyme SAM, inhibitor 1.47Å (Coutard et al., 2014) 
4CTK DENV NS5 capping enzyme SAM, inhibitor 1.53Å (Coutard et al., 2014) 
4R05 DENV NS5 capping enzyme  - 2.1Å (M. B. Brecher et al., 2015) 
4R8R DENV NS5 capping enzyme  - 1.46Å (Noble et al., 2014) 
4R8S DENV NS5 capping enzyme Sinefungin 1.48Å (Noble et al., 2014) 
5CUQ DENV NS5 capping enzyme Compound NSC (inhibitor) 1.7Å 
(M. Brecher et al., 
2015) 
5E9Q DENV NS5 capping enzyme SAM, inhibitor 1.79Å (Benmansour et al., 2017) 
5EC8 DENV NS5 capping enzyme SAM, inhibitor 1.71Å (Benmansour et al., 2017) 
5EHG DENV NS5 capping enzyme SAM, inhibitor 2.02Å (Benmansour et al., 2017) 
5EHI DENV NS5 capping enzyme SAM, inhibitor 1.3Å (Benmansour et al., 2017) 
5EIF DENV NS5 capping enzyme SAM, inhibitor 1.5Å (Benmansour et al., 2017) 
5EIW DENV NS5 capping enzyme SAM, inhibitor 1.61Å (Benmansour et al., 2017) 
5EKX DENV NS5 capping enzyme SAM, inhibitor 1.76Å (Benmansour et al., 2017) 
5GOZ ZIKV NS5 capping enzyme SAH, GTP, PPi 2.05Å (C. Zhang et al., 2016) 
5GP1 ZIKV NS5 capping enzyme SAH, m7GpppA 2.44Å (C. Zhang et al., 2016) 
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5IKM DENV NS5 capping enzyme SAM 1.9Å (Minasov et al., to be published) 
5KQR ZIKV NS5 capping enzyme SAM 1.33Å (Coloma et al., 2016) 
5KQS ZIKV NS5 capping enzyme SAM, m7GDP 1.5Å (Coloma et al., 2016) 
5M5B ZIKV NS5 capping enzyme SAM 2.01Å (Coutard et al., 2017) 
5MRK ZIKV NS5 capping enzyme Sinefungin 1.9Å (Hercik and Boura, to be published) 
2HCN WNV NS5 RdRp  - 2.35Å (Malet et al., 2007) 
2HCS WNV NS5 RdRp  - 2.5Å (Malet et al., 2007) 
2HFZ WNV NS5 RdRp  - 3.0Å (Malet et al., 2007) 
2J7U DENV NS5 RdRp  - 1.85Å (Yap et al., 2007) 
2J7W DENV NS5 RdRp GTP 2.6Å (Yap et al., 2007) 
3VWS DENV NS5 RdRp NITD107 (inhibitor) 2.1Å (Noble et al., 2013) 
4C11 DENV NS5 RdRp  - 2.6Å (Lim et al., 2013a) 
4HDG JEV NS5 RdRp GTP 2.38Å (Surana et al., 2014) 
4HDH JEV NS5 RdRp ATP 2.28Å (Surana et al., 2014) 
4HHJ DENV NS5 RdRp  - 1.79Å (Noble et al., 2013) 
4MTP JEV NS5 RdRp  - 3.65Å (Surana et al., 2014) 
5F3T DENV NS5 RdRp Inhibitor 2.05Å (Noble et al., 2016) 
5F3Z DENV NS5 RdRp Inhibitor 2.0Å (Noble et al., 2016) 
5F41 DENV NS5 RdRp Inhibitor 2.0Å (Noble et al., 2016) 
5HMW DENV NS5 RdRp Inhibitor 2.15Å (Yokokawa et al., 2016) 
5HMX DENV NS5 RdRp Inhibitor 2.4Å (Yokokawa et al., 2016) 
5HMY DENV NS5 RdRp Inhibitor 2.1Å (Yokokawa et al., 2016) 
5HMZ DENV NS5 RdRp Inhibitor 1.99Å (Yokokawa et al., 2016) 
5HN0 DENV NS5 RdRp Inhibitor 2.05Å (Yokokawa et al., 2016) 
5I3P DENV NS5 RdRp Inhibitor 2.45Å (Lim et al., 2016) 
5I3Q DENV NS5 RdRp Inhibitor 1.88Å (Lim et al., 2016) 
5IQ6 DENV NS5 RdRp HeE1-2Tyr (inhibitor) 3.0Å (Tarantino et al., 2016) 
5K5M DENV NS5 RdRp Inhibitor 2.01Å (Lim et al., 2016) 
4K6M JEV NS5 full-length SAH 2.6Å (Lu and Gong, 2013) 
4V0Q DENV NS5 full-length SAH 2.3Å (Zhao et al., 2015b) 
4V0R DENV NS5 full-length SAH, GTP 2.4Å (Zhao et al., 2015b) 
5CCV DENV NS5 full-length SAH 3.6Å (Klema et al., 2016) 
5DTO DENV NS5 full-length SAH, m7GDP 2.6Å (Zhao et al., 2015a) 
5JJR DENV NS5 full-length SAH, RdRp inhibitor 1.99Å (Lim et al., 2016) 
5JJS DENV NS5 full-length SAH, RdRp inhibitor 1.65Å (Lim et al., 2016) 
5TFR ZIKV NS5 full-length SAH 3.05Å (Longenecker et al., to be published) 
5TMH ZIKV NS5 full-length SAH 3.28Å (Wang et al., to be published) 
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Appendix 4. Structures of NS3 protease, NS3 helicase or full-length NS3 of DENV, 
YFV, WNV, JEV and ZIKV. 
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Mutant Sequenced Expressed Purified (HisTrap) 
Purified 
(HiLoad) 
WT     
NS5 D668V     
NS3 R185A     
NS3 K186A     
NS3 K187A     
NS3 R216A     
NS3 R218A     
NS3 R250A     
NS3 G254A     
NS3 N255A     
NS3 H274A     
NS3 R275A     
NS3 V276A     
NS3 V276A N278A     
NS3 V276K     
NS3 V276K NS5 K314V     
NS3 V276L     
NS3 N278A     
NS3 N278D     
NS3 N278K     
NS3 N278K NS5 K314N     
NS3 N278Q     
NS3 N280A     
NS3 E306A     
NS3 L307A     
NS3 E309A     
NS3 P502A     
NS3 N503A     
NS3 E523A     
NS3 R525A     
NS3 R527A     
NS3 E529A     
NS3 E530A     
NS3 K532A     
NS3 K532G     
NS3 K532G NS5 G750K     
NS3 K532R     
NS5 R45A     
NS5 E46A     
NS5 N48A     
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NS5 E289A     
NS5 S291A     
NS5 S292A     
NS5 E312A     
NS5 K314A     
NS5 K314A G750A     
NS5 K314N     
NS5 K314R     
NS5 K314V     
NS5 G317A     
NS5 E416A     
NS5 E417A     
NS5 Q420A     
NS5 K422A     
NS5 E426A     
NS5 D430A     
NS5 G750A     
NS5 G750K     
NS5 G750P     
Appendix 5. Preparation of recombinant proteins for in vitro binding assays. 
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Mutant Average Standard deviation n 
WT 100.00% 0.00% 19 
NS5 D668V 1.40% 0.92% 19 
NS3 R185A 64.82% 4.01% 4 
NS3 K186A 1.16% 0.25% 3 
NS3 K187A 104.60% 19.77% 3 
NS3 R216A 0.24% 0.17% 3 
NS3 R218A 2.68% 1.27% 4 
NS3 R250A 108.54% 25.03% 4 
NS3 G254A 0.32% 0.06% 3 
NS3 N255A 52.24% 19.25% 3 
NS3 H274A 58.61% 13.80% 4 
NS3 R275A 10.65% 6.57% 4 
NS3 V276A 5.76% 0.90% 4 
NS3 V276A N278A 1.54% 0.71% 3 
NS3 V276K 9.47% 0.97% 3 
NS3 V276K NS5 K314V 2.21% 0.33% 3 
NS3 V276L 62.90% 13.10% 4 
NS3 N278A 41.26% 15.31% 3 
NS3 N278D 4.38% 3.06% 4 
NS3 N278K 2.43% 0.63% 3 
NS3 N278K NS5 K314N 1.18% 0.23% 3 
NS3 N278Q 51.98% 16.25% 4 
NS3 N280A 27.88% 4.55% 3 
NS3 E306A 84.63% 14.78% 3 
NS3 L307A 12.42% 4.95% 3 
NS3 E309A 24.43% 4.09% 3 
NS3 P502A 39.54% 7.29% 3 
NS3 N503A 41.35% 3.88% 3 
NS3 E523A 1.21% 0.85% 3 
NS3 R525A 2.31% 0.94% 3 
NS3 R527A 0.76% 0.27% 3 
NS3 E529A 67.36% 13.33% 4 
NS3 E530A 44.18% 10.86% 3 
NS3 K532A 41.87% 14.47% 4 
NS3 K532G 90.33% 22.23% 3 
NS3 K532G NS5 G750K 58.54% 7.35% 3 
NS3 K532R 101.26% 26.24% 4 
NS5 R45A 128.55% 19.09% 3 
NS5 E46A 139.29% 5.49% 3 
NS5 N48A 1.26% 0.32% 3 
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NS5 E289A 73.22% 7.39% 3 
NS5 S291A 79.86% 7.63% 3 
NS5 S292A 155.69% 33.97% 4 
NS5 E312A 130.55% 40.53% 4 
NS5 K314A 55.17% 13.58% 4 
NS5 K314A G750A 64.85% 26.80% 4 
NS5 K314N 86.82% 8.79% 3 
NS5 K314R 101.90% 8.03% 4 
NS5 K314V 2.63% 0.77% 3 
NS5 G317A 0.34% 0.09% 3 
NS5 E416A 128.40% 30.03% 4 
NS5 E417A 56.21% 3.57% 3 
NS5 Q420A 59.16% 14.03% 3 
NS5 K422A 36.48% 10.79% 3 
NS5 E426A 84.99% 33.64% 3 
NS5 D430A 15.97% 5.26% 3 
NS5 G750A 87.70% 13.33% 4 
NS5 G750K 54.60% 14.85% 3 
NS5 G750P 3.49% 1.41% 4 
 
Appendix 6. Luciferase activity of the wild-type replicon and all mutants. 
